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INTRODUCTION
The purpose of this group of papers is to present
an up-to-date review of common urologic problems
that confront the primary care physician. Two papers
are presented on urinary tract infections, the most
common complaint faced by physicians in their
offices. Another paper covers congenital anomalies
of the urinary tract which represent an important
part of pediatric diseases. Dr. William McRoberts,
one of the McGuire Lecturers, reviews aspects of
male infertility, a significant concern in today' s society. Other topics discussed in this issue are parenchymal kidney disease, the management of the
patient with end-stage renal disease, and urinary
tract cancer. These subjects are both timely and
important in the every day practice of the primary
care physician.

The Female Urethral Syndrome and
Urethritis and Prostatitis in the Male
STEPHEN N . ROUS, M.D.

Professor and Chairman, Department of Urology , M edica/ University of South Carolina, Charleston, South
Carolina

Two common urological problems frequently
encountered by the primary care physician are the
female urethral syndrome and urethritis in the male.
Although I will touch on chronic prostatitis in this
discussion , I question whether it is anything but a
relatively uncommon entity.
FEMALE URETHRAL SYNDROME

While the female urethral syndrome is neither
life-threatening nor even serious, it causes great discomfort to the patient and is probably the most common genitourinary (GU) complaint bringing women
to the primary care physician . Combined with cystitis
it may account for as many as two thirds of the
outpatient visits to the urologist, at least in my experience.
The symptoms of the syndrome are:
I. Frequency of voiding with or without burning,
2. Discomfort in the region of the urethra,
3. Pressure low in the pelvis,
4. Urgency and/or nocturia, and
5. Terminal dysuria.
By far the most common symptom is the frequency of
urination with or without burning, and it may occur
with any or all of the other symptoms.
Anatomically, the female urethra is homologous
to the prostatic urethra, proximal to the ejaculatory
This is an edited transcript of the lecture delivered by Dr.
Rous at the 49th Annual McGuire Lecture Series, December 3,
1977, at the Medical College of Virginia, Richmond, Virginia.
Correspondence and reprint requests to Dr. Stephen N. Rous,
Department of Urology, Med ica l University of South Carolina,
Charleston, SC 29403.
MCV QUARTERLY 14(2): 65-68, 1978

duct. It is about 3 to 5 cm in length and is surrounded
by suburethral and paraurethral glands, the ducts of
which empty for the most part into the distal portion
of the urethra near the urethral meatus. Normally,
the urethra is colonized by a certain number of introital bacteria, usually limited to the distal portion
of the urethra, and when the bacteria are limited to
this area, there are usually no symptoms. However,
when bacterial colonization extends to the proximal
suburethral and paraurethral glands, the symptoms
of the female urethral syndrome occur.
Diagnosis
When a patient comes to the physician with
symptoms of the female urethral syndrome, diagnostic evaluation should be based on the following procedures:
I. Urinalysis and urine cultures. The findings in a
patient with one or more symptoms will usu ally show
a modest pyuria of 15 to 20 white cells per high power
field . Culturing the urine-aerobic, anaerobic and, in
selected cases, acid fast-is imperative because, unless negative cultures, which are a feature of the syndrome, are established, the patient's symptoms may
be confused with bacterial cystitis.
2. Urograms and cystograms. When symptoms
persist, an excretory urogram should be done. Usually the results will be normal, b.ut occasionally there
will be a patient with a stone in the distal ureter that
can produce the symptoms of urgency and frequency .
While the patient's bladder is full of the contrast
medium that has come down from the kidneys, she
should also be asked to void under x-ray control.
This will often demonstrate whether or not a urethral
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diverticulum exists, and the presence of one can
sometimes mimic the symptoms of the syndrome. If a
urethral diverticulum is suspected, the patient should
additionally undergo a retrograde urethrogram .
3. Vaginal examination. Not only is a vaginal examination important to check for gynecological pathology but it is useful specifically to detect the presence of a urethral diverticulum . This is a readily
detectable mass which varies in size from a pea to a
golf ball and is found in the midline on the anterior
vaginal wall. It may or may not have stones in it.
4. Cystoscopy and urethroscopy. These procedures establish conclusively the diagnosis of the female urethral syndrome. In appearance the urethra
will look very similar to a red cobblestone road and
this is called a granular urethritis; the pathology
sometimes extends up into the trigone and is then
called a granular urethro-trigonitis .
Treatment
There are several ways in which to treat the
female urethral syndrome. Systemic antimicrobial
therapy is usually unsuccessful because the antimicrobials are not able to penetrate the suburethral
and paraurethral glands in sufficient quantities. However, with some of these patients I have used Furacin* Urethral Inserts® which put the antimicrobial
agent in direct proximity to the suburethral and paraurethral ducts. It is well worth the time spent to show
these patients how to use the inserts. There are two
methods I have found helpful. One method is to put a
mirror on a stool, have the woman put one leg up on
it, and looking into the mirror, guide the suppository
into her urethra. She should then lie down and put
her legs tightly together for 20 to 30 minutes. The
other method is best for supple individuals who can
sit upright, put a mirror between their legs, and then
guide the suppository into the urethra .
Another means of treating the syndrome is by
urethral dilatation in selected patients. The rationale
behind this is that the procedure opens the paraurethral and suburethral ducts and promotes drainage from the underlying glands as well as stretches
the urethral meatus to promote a more rapid flow of
urine. This procedure is best used in combination
with the urethral inserts.
Finally, there are a number of surgical methods
*Unfortunately, Furacin inserts have just been removed from
the market. An acceptabl e substitute is Protargol Urethral suppositories ( 17%) which can be m ade-to-order in pharmaci es.

for treating this condition such as unroofing the suburethral and paraurethral ducts and fulgurating
them .
URETHRITIS AND PROSTATITIS IN THE MALE

Urethritis is probably the single most common
urological problem bringing men to the primary care
physician or the urologist. It is defined as inflammation , with or without infection , of any portion of the
urethra and is broken down into specific and nonspecific varieties.
Urethritis is very much more common than
chronic prostatitis or prostatostasis with which it is
often confused. This confusion between urethritis
and prostatitis is not surprising in view of the anatomical relationship between the urethra and the
prostate. The numerous ducts connecting the posterior urethra with the underlying prostate gland allow
for a great similarity of symptoms of infection or
inflammation between the two .
Causes
The etiology of urethritis is almost invariably
that of sexual contact. It can be by conventional or
anal intercourse, or, often , fellatio . Since it is well
known that bacteria in the mouth can be more virulent than bacteria in the vagina or the anus, fellatio as
a source of urethritis should always be kept in mind
and the patient should be asked about the nature of
his sexual contact.
There are a number of bacterial causes of urethritis. Specific urethritis is caused by the gonococcus
organism. It affects the anterior portion of the urethra initially but will usually involve the posterior
portion if left untreated. Mycoplasma, Trichomonas
vaginalis, and Candida are causes of nonspecific urethritis, as are viruses, gram-positive organisms, and
some others. Bacterial infections usually affect the
posterior portion of the urethra.
The most common non bacterial cause of inflammation is urethral "stripping." The affected patient
does this every time he urinates and as many times in
between voidings as privacy will allow. He takes out
his penis, milks it out proximal to distal , and turns it
up to look at the meatus to see if there is still some
discharge. The urethral mucosa is almost as sensitive
as the conjunctiva of the eye and if a urethra is
traumatized by this vigorous stripping, a minimal
discharge will often be produced, particularly in a
urethra that has had recent infection in it. It is there-
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fore very important to discourage patients from this
practice.
Another much less common cause of urethritis is
persistently alkaline urine. A certain number of patients seem to have urine that has a ph of 6.8 or
higher. It may be that such patients consume large
quantities of citrus juice which is metabolized to bicarbonate and produces an alkaline urine, or it may
be for other reasons. In any case, during the act of
voiding, the calcium phosphate crystals, which are
precipitated out of solution because of the high ph,
act as irritants to the urethra and continue to irritate
it until the next voiding.
Symptoms
The symptoms of anterior gonococcal urethritis
include a copious urethral discharge that ranges from
green to yellow in color; it may at times be whitish . It
is usually accompanied by burning on voiding and a
feeling of discomfort in the penile or anterior urethra.
Rarely, there may be minimal or no urethral discharge. The symptoms of posterior or nonspecific
urethritis are virtually the same as chronic prostatitis
or prostatostasis. They consist of an itching or burning "inside" or at the base of the penis; discomfort or
itching in the urethra on voiding; and most common,
a minimal, clear mucoid urethral discharge on arising
in the morning, or a 2 to 3 cm brownish or yellowish
stain inside the patient's shorts that is seen at night.
Diagnosis and Treatment
The technique of three-glass urine collection in
conjunction with pros ta tic massage and/ or the postprostatic massage fourth-glass specimen is used for
determining the anatomical source of urethral infection and more specifically for separating chronic
prostatitis from nonspecific urethritis. A three-glass
urine specimen is first obtained, then the patient is
asked to hold his urethra tightly shut while the physician massages the prostate vigorously. After the prostatic massage, the patient is asked to release his urethra and a few drops of prostatic secretions will
usually come out into the culture tube or onto a slide.
If no secretions are obtained, the patient should void
a few cc of urine into a fourth glass and this will
contain the prostatic secretions. The specimens in the
first, second, and third glasses are then cultured as
are the prostatic secretions or the fourth-glass specimen. If the first and/ or third-glass urine has more
bacteria colonies than the prostatic secretions or the
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post-prostatic massage fourth-glass specimen, the infection is in the urethra. If the opposite is true, the
infection is in the prostate. Bacterial colony counts
from the urethra and prostate range from several
hundred per cc up to a few thousand per cc. When
these studies are carried out, it will be seen that true
bacterial infection of the prostate gland is uncommon. There is, however, a condition called prostatostasis which occurs more frequently, but not, in
my opinion, nearly as frequently as posterior urethritis. Prostatostasis can develop when a man goes from
feast to famine sexually. The prostatic fluid is made
continuously in abundant supply and when there is
no ejaculation, the prostate gland enlarges and produces the symptoms already noted in conjunction
with nonspecific posterior urethritis. The patient
should be encouraged to masturbate frequently, and/
or to have intercourse to relieve this condition. Both
work equally well as does prostatic massage, although the latter is the least favored therapy.
For specific, or gonococcal, urethritis, a culture
can be obtained from the discharge and, in the rare
patient without discharge, from swabbing the distal
urethra. The culture has to be made under increased
C0 2 tension on a Thayer-Martin medium. It is best to
do a smear and see gram-negative intracellular diplococci for the provisional diagnosis, but the culture
should confirm it finally. The treatment of choice for
gonococcal urethritis is aqueous procaine penicillin
G with probenecid; alternative treatment is ampicillin
with probenecid. For patients who are allergic to the
penicillin group of drugs, spectinomycin and tetracycline are acceptable alternatives.
The mycoplasma organisms found with some
cases of nonspecific urethritis can be confusing because these organisms have been reported in asymptomatic as well as symptomatic individuals. The organisms are cultured with a urethral swab or using
the urine sediment, and the mycoplasma organisms
are identified morphologically and by specific biochemical and bacteriologic tests. Patients with this
infection are treated with one of the tetracycline
group of drugs, although probably no more than 60%
to 70% are cured by the medication.
Trichomonas vaginalis is not, in my experience,
a common cause of urethritis in the male. However, it
should be considered a possibility particularly if the
consort has a trichomonas infection. The organism is
seen either on a wet mount of the urine specimen or
in urethral discharge. This infection is best treated
with metronidazole (Flagyl®).
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For those patients.with inflammatory and nonorganism causes of urethritis, treatment is relatively
simple. The rare individuals with persistently alkaline
urine can be successfully treated with ascorbic acid
for two to three days until the symptoms disappear.
However, care should be taken not to use this means
on patients with known uric acid or cystine lithiasis.

Inflammation due to urethral stripping can be cured
by counseling the patient to refrain from this activity.
The most important point in treating patients
with nonspecific urethritis is to reassure them that
these infections are self-limited, not serious, and will
not lead to impotency, sterility, prostatic hyperplasia,_
or prostatic cancer.

Appropriate Antibiotic Therapy for Urinary
Tract Infections
SHELDON M. MARKOWITZ, M.D.

Division of Infectious Diseases, Department of Medicine, M edica/ College of Virginia, Health Sciences Division of
Virginia Commonwealth University, Richmond, Virginia

It was stated years ago that physicians pour
medicines about which they know little, for diseases
about which they know less, into human beings about
whom they know nothing.' Although as a prophet
this wag may have overstated the case as it concerns
the therapy of urinary tract infections (UTI), the
character of contemporary infectious diseases is, in
part, due to the use and abuse of anti-infective
agents. 2 •3 One has only to look at the rising incidence
of gram-negative bacteremia and the emergence of
multiple antibiotic-resistant organisms over the past
several decades to appreciate the impact physicians
have made with these agents.4·5 Despite the drawbacks, the benefits resulting from the use of antibiotics far outweigh the deleterious effects, a fact perhaps
realized most vividly by physicians whose careers
reach back to the pre-chemotherapeutic era. The enthusiasm for antibiotics makes them one of the most
prescribed groups of drugs in the United States, accounting for 15% to 20% of all new and refill prescriptions .6 Undoubtedly many of the prescriptions
are used to treat persons with UTis, in light of the
fact that UT!s are said to rank second only to upper
respiratory infecti ons as the most common infections
in the western hemisphere.7

Principles of Therapy
Without belaboring the point, how does the physician steer his way through the many antibiotics

Correspondence a nd reprint requests to Dr. Sheldon M.
Markowitz, Box 92, Medical College of Virginia, Richmond , Virginia 23298.
MCV QUARTERLY 14(2): 69- 75 , 1978

which are promoted so vigorously by pharmaceutical
companies, perhaps in response to the competitive
pressures and potential profits of what has become a
multi-billion dollar industry? Certain characteristics
are desirable in any antibiotic, and it behooves the
physician to consider these characteristics when evaluating the potential usefulness of the agent. 8
1. Activity. An agent with bactericidal activity
against a wide spectrum of microorganisms, and one
that doesn't disturb normal flora or lead to the emergence of resistant organisms should be sought.
2. Toxicity. Adverse reactions should be infrequent, and teratogenicity absent.
3. Pharmacology. Pharmacologic properties should
be such that adequate concentrations of the drug are
achieved and maintained near the organism for prolonged periods.
4. Physicochemica/ properties. The drug should
be stable (dry or in solution) tolerant of pH changes,
and readily absorbable from the gastrointestinal (GI)
tract.
5. Interactions . The drug should not interact with
other therapeutic agents.
6. Cost . The agent should be inexpensive and
hence available to all who need it.
Of course, no such "magic bullet" exists, and
because it doesn't, one should be guided , when treating UTis, by certain fundamental principles.9
I. The presence of a bacterial infection should be
established . Symptoms alone are not sufficient evidence for the diagnosis of UTI, as up to 50% of
women with dysuria and frequency have sterile
urine. 10 The finding of one or more bacteria per oil
field in a Gram stain of uncentrifuged urine correlates
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well (over 90%) with the presence of 100,000 organisms or more per ml of urine. Numbers of this
magnitude usually indicate true infection (significant
bacteriuria) and not procurement contamination
with gram-negative enteric bacilli. In an asymptomatic person, three consecutive daily urine cultures
obtained by the clean-voided method and each containing 100,000 organisms per ml of the same bacterium indicate that the patient has at least a 95%
chance of having a UTI. 11 In a symptomatic person,
bacteria seen on microscopic examination and one
urine culture containing 100,000 organisms or more
per ml carries the same 95% probability of true infection.
2. The elimination of bacteriuria requires the use
of antibiotics which are active against the common
urinary pathogens and which achieve inhibitory concentrations in the urine, not the serum. Disappearance of bacteriuria correlates well with the
sensitivity of the organism to achievable urinary levels.12·13 This serves to underline the obvious discrepancies sometimes seen between antibiotic sensitivities in vitro and the eradication of bacteriuria.
3. Underlying urinary tract abnormalities, particularly obstructive or neurogenic lesions, should be
corrected if possible; obstruction from whatever
cause not only has a compromising effect on renal
function but it also practically eliminates the likelihood of successful antibiotic therapy.
4. The hallmark for the eradication of infection
is the absence of bacteriuria following the cessation
of therapy. Symptomatic improvement is a poor indicator of successful therapy because symptoms may
improve with only the slightest suppression of bacteriuria. In addition, while bacteriuria may disappear
during therapy, recurrence of the original organism
(see below) is common and can be detected only by
obtaining cultures after the completion of therapy.
5. Prolonged follow-up is required to insure permanent cure of the UT!. Recurrence of an initially
symptomatic and apparently successfully treated infection may be asymptomatic, and constant vigilance
by the physician can pay dividends in reduced morbidity from UTis. This is done usually by obtaining
periodic urine cultures (Figure). A culture obtained
between 48 to 72 hours after the initiation of therapy
should be sterile. If it is not, then the therapy should
be recognized as a failure and the patient should be
treated with an appropriate antibiotic chosen on the
basis of sensitivity tests. If the culture is negative,
additional cultures should be obtained one to two

weeks following completion of therapy, monthly for
three months, then at three-month intervals for one
to I 1/2 years. The patient should be considered cured
if there is no recurrence during the period of observation.
Therapeutic Agents
The goal of therapy for UT!s is the elimination
of bacteriuria and the most effective way of achieving
this is with antibiotic therapy. The antimicrobial
agents frequently used to treat UT!s are listed in the
Table. Most share the common characteristics of
being active against the majority of common urinary
tract pathogens and being excreted at high concentrations into the urine.
Sulfonamides. The sulfonamides were the first
group of agents shown to be consistently useful for
treating UT!s. Many effective sulfonamides are available, but the short-acting, oral nonabsorbable drugs,
such as sulfisoxazole and sulfamethoxazole, are generally recommended. These agents achieve high urinary concentrations and are soluble at an acid pH.
Toxicity is relatively infrequent. They are especially
effective against Escherichia coli and Proteus mirabilis
but generally are useful only for the first few episodes
of infection because of the emergence of resistant
bacteria. Although sulfonamides offer no real advantage over other agents, they are inexpensive (see
Table) and hence available to most patients. Sulfonamides should not be used in persons with glucose-6phosphate dehydrogenase deficiency, in pregnant
women near term, and in newborn infants because of
the danger of producing kernicterus in the neonate.
Penicillins. Among the penicillins, ampicillin remains the drug of choice for UTis. It is effective
against many gram-positive and gram-negative organisms and reaches adequate levels in the renal medulla. Ampicillin is the preferred agent for pregnant
women and newborns, and is especially useful in
treating UT!s due to susceptible organisms in patients .with renal insufficiency. There is no evidence to
indicate that ampicillin is superior to sulfonamides in
the management of uncomplicated UT!s (see below),
just as there is no evidence to indicate that newer
penicillin derivatives, such as amoxicillin, are superior to ampicillin. Diarrhea is frequent and rashes
occur in 5% to 10% of patients. 1
Tetracyclines. The tetracyclines have been relegated to a less prominent role in the treatment of
UT!s. The best urinary levels are achieved with tetracycline and oxytetracycline. 11 Newer derivatives,
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Acute
Symptoms*

Asymptomatic
bacteriuria*

!

!

culture urine and
begin therapy

2 consecutive cultures
with same organism
precedes therapy

Culture urine

+

If bacteriological and/or
clinical response, treat
for 10-14 days

Reinfection

~

Retreat with appropriate
drug 10-14 days

Relapse

~

Consider therapy
for 6 weeks

Negative
cultures

l

CURE

CURE

Reinfection

If frequent,
consider long
term prophylaxist

If occassional treat
each episode for
10-14 days

Relapse

l

Consider therapy
for 6-12 months

CURE

* Radiographic evaluation should be obtained on all children,
all men, young women, and probably in all patients with
bacteremia
t Not in asymptomatic elderly without obstruction
Figure-Diagrammatic approach to the management of urinary tract infection s.
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TABLE
Antibiotics Useful in the Therapy of Urinary Tract Infections in Adults
Antibiotic

Oral:
Sulfisoxazole
Sulfamethoxazole
Penicillin G
Ampicillin
Amoxicillin
T etracycline
Cephradine
Cephalexin
Nitrofurantoin
Nalidixic acid
Trimethoprim-Sulfamethoxazole
Parenteral:
Ampicillin
Carbenicillin
Cephalothin
Cefazolin
Gentamicin
Amikacin

Tradename(s)

Dosage•

Cost in dollars (dose)b

Gantrisin
Gantanol
Many
Many
Larotid , Amoxil
Many
Velosef, Anspor
Ke flex
Furadantin
Macrodantin
NegGram
Bactrim , Septra

0 .5-1.0 gm q 4-6 h
l.Ogm q 8-12 h
0.4-0.8 X I 0'µ q 6 h
0.5-1.0 gm q 6 h
0.25-0.5 gm q 8 h
0.25-0.5 gm q 6 h
0.5gm q 6 h
0.5gm q 6 h
0.05-0. 1 gm q 6 h
0.05-0. I gm q 6 h
0:5-1.0 gm q 6 h
2 tablets q 12 h

.04 (0 .5 gm)
.08 (0.5 gm)
.01 (0.2 X IO'µ)
.09 (0.5 gm)
.30(0.5gm)
.03 (0.5 gm)
.56 (0.5 gm)
.52 (0.5 gm)
.01 (0.05 gm)
.15(0.05gm)
.12 (0.5 gm)
.21 (per tablet)

Many
Geopen , Pyopen
Ke ft in
Ancef, Kefzol
Garamycin
Amikin

0.5-2 gm q 4-6 h
1-5 gm q 4-6 h
0.5-2 gm q 4-6 h
0.5-1.5 gm q 6-8 h
1-1.7 mg/ kg q 8 h
5 mg/ kg q 8 h

1.11 (I gm)
2.20(1 gm)
2.75 (I gm)
5.05 (I gm)
5.05 (per 80 mg vial)
4 .93 (per JOO mg)

• Usual average or range of dosages in patients with normal renal function.
b Cost to pharmacist based on listings in the American Druggist Blue Book (Hearst Corp. Publishers), October 1977.

such as doxycycline and minocycline, a lthough approved for use in UTis, have significant extrarenal
routes of excretion, so that the low urinary concentration achieved makes them Jess desirable for therapy.14 Generic tetracycline is inexpensive (see Table).
Resistance to tetracycline emerges rapidly during
therapy; however, tetracyclines are probably as effective as the- sulfonamides and ampicillin for treating
uncomplicated UTis (see below). Fulminant hepatitis
has been induced in those receiving large parenteral
doses of tetracycline (greater than 2 gm per day), and
irreversible discoloration and maldevelopment of
permanent teeth is a danger in children under age 8
who receive these drugs 14; however, GI signs and
symptoms are the most common side effects of therapy .14
Cephalosporins. The instances where cephalosporin antibiotics should be used are difficult to
define, but they are indicated possibly for treating
gram-positive coccal infections (except those caused
by enterococci and methicillin-resistant staphylococci) in patients allergic to penicillin. These agents
are useful in treating infections due to Klebsiella
pneumoniae and antibiotic strains of E coli, P mirabilis, and other gram-negative bacilli. The use of
cephalosporin antibiotics for central nervous system

infections is contraindicated. 15 Although most of
these drugs achieve good urinary levels, and are
therefore effective agents for the therapy of UTis,
most are expensive (see Table) and should not be
used when cheaper, equally effective drugs are available. The two most important oral agents, cephalexin
and cephradine, are simi lar and can be used interchangeably.16 Up to 5% of patients develop allergic
reactions such as rash, fever, and, rarely, anaphyJaxis11; 5% to 15% of penicillin-allergic patients will
manifest allergy to the cephalosporins. 18
Aminoglycosides. The aminoglycoside antibiotics
are parenterally administered agents useful against a
wide variety of gram-negative organisms. These
drugs have the potential for causing significant otoand nephrotoxicity 1• and should therefore be reserved
for therapy of hospitalized patients with moderate to
severe UTis caused by organisms resistant to Jess
toxic agents. Dosage should be adjusted for those
with renal insufficiency; such alterations in dosage
can be achieved by any of several published programs.20 - 22 Gentamicin and amikacin are two commonly used aminoglycoside antibiotics which differ
little in the incidence of toxicity. 23 However, amikacin
is resistant to many more of the aminoglycosideinactivating enzymes than gentamicin, 24 therefore its
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greatest utility at present is in the therapy of UTis
caused by gentamicin-resistant organisms.
Nitrofurantoin. This drug is available in crystalline and macrocrystalline forms. The latter compound is absorbed from the GI tract and excreted
more slowly than the crystalline form and allegedly
causes less GI upset. Nitrofurantoin achieves high
urine concentrations and is more active at an acid
pH . It is effective against gram-positive and gramnegative organisms except Pseudomonas sp, some Enterobacter sp, Serratia marcescens, and indole-positive Proteus. The drug may be useful for lower and
upper UTI. 11 Nitrofurantoin is contraindicated for
use in patients with renal failure because little of the
drug is found in the urine and because the incidence
of irreversible peripheral neuropathy is increased under these circumstances. 11 Small amounts of this
orally administered drug is found in the feces, which
probably accounts for the relatively low incidence of
resistant enteric organisms emerging during and after
therapy. Thus, nitrofurantoin would appear to be a
useful therapeutic and prophylactic agent for patients
with recurrent UT1s 25 (see below).
Nalidixic acid. Nalidixic acid and its cogener,
oxolinic acid, are oral antimicrobials which have virtually the same antibacterial spectrum, including
most gram-negative urinary tract pathogens except
for Pseudomonas sp, Serratia marcescens and indolepositive Proteus. Resistance develops rapidly and recurrence of infection with resistant organisms is not
uncommon. Blood and, presumably, tissue levels
are low. These agents are moderately expensive (see
Table) and should be used as alternative therapy to
other oral agents such as the sulfonamides and ampicillin.
Methenamine salts. Methenamine salts have a
limited role in the therapy of UTis. These agents are
effective against most gram-negative organisms in
vitro, but require an acid medium (pH of 6 or less)
for release from methenamine of the bactericidal
agent formaldehyde; tissue levels are low to absent.
The main uses are for suppression of bacteriuria or
prophylaxis between episodes of infection. The efficacy of methenamine salts in patients with chronic indwelling bladder catheters recently has been questioned.26
Trimethoprim-sulfamethoxazole (TM P-SMX ).
TMP-SMX is a fixed combination of drugs which
acts additively or synergistically against a wide range
of gram-positive (including enterococci) and gramnegative organisms, except Pseudomonas and Alcali-
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genes sp. The list of indications for TMP-SMX continues to grow and presently includes infections due
to Shigella sp, Salmonella typhi, ampicillin-resistant
Haemophilus infiuenzae, and Pneumocystis carinii,
and diseases such as acute exacerbations of chronic
bronchitis, acute otitis media, and gonococcal urethritis.27 Its most practical applications are the treatment of and prophylaxis for recurrent UTis caused
by susceptible organisms. 25 Emergence of resistant
organisms in the fecal flora has not been a major
problem and because trimethoprim penetrates prostatic tissue, TMP-SMX is probably the drug of choice
for recurrent or chronic prostatic infection. 28 The
adverse effects of TMP-SMX represent the sum of
reactions to trimethoprim (folate deficiency syndromes and possible teratogenic effects) and sulfamethoxazole (see above). The drug may be used in mildto-moderate renal failure. 29

Urinary Tract Infections

Urinary tract infections represent a broad group
of clinical entities with bacteriuria as the common
thread . Many classifications are possible, but those
which include not only the type of infection but also
the site of involvement allow for the most accurate
assessment of antibiotic therapy . Although the site of
infection in many instances is unknown, enough evidence is available to analyze antibiotic therapy in the
following clinical categories of UTI: acute uncomplicated UTI; recurrent UTI ; complicated UTI; asymptomatic bacteriuria; and catheter-related UTI.
A cute uncomplicated UT/s usually represent the
first or second infection in young sexually active
women without underlying urinary tract abnormalities, and are caused by antibiotic enteric bacilli (most
commonly E coli) which emanate from antibiotic
fecal flora . This type of infection responds well to
practically all commonly used oral antibiotics, but
because they are effective, inexpensive, and well-tolerated, the oral, nonabsorbable sulfonamides remain
the therapy of choice. Treatment is usually given for 7
to 14 days . Longer courses of therapy are usually not
necessary. Many alternative agents exist (see Table),
but none have proven superior to the sulfonamides
and most are more expensive. In the absence of an
obstructive or neurogenic lesion , the urine should be
sterile between 48 to 72 hours (Figure). If bacteriuria
persists, therapy should be guided by the results of
sensitivity testing.
Some patients with acute symptomatic infection
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fail to respond to the initial antibiotic therapy or
suffer recurrence of the infection. The recurrence may
be a relapse of the initial infection with the same
pathogen, suggesting a parenchymal focus of infection in the kidney or prostate or may be caused by
different organisms, so-called reinfections. The source
for reinfection is almost always the bowel flora. Approximately 80% of recurrences are reinfections and
most are limited to the bladder. Antibiotic sensitivity
testing assumes added importance in this situation
because the pathogen will proba bly not be sensitive
to sulfonamides if used initially. Ampicillin, tetracyclines, cephalosporins, and TMP-SMX are preferred
and are given orally for I 0 to 14 days. Each course of
therapy will result in a 20% to 25% long-term cure
rate. 11 Those having a second or third episode of
infection should probably be evaluated urologically
or radiographically (see Figure). Those with occasional recurrences (three or less per year) can be
treated like acute uncomplicated infection. With
more frequent recurrences, especially in the absence
of urological abnormalities, the precise duration of
therapy is not well established. Closely spaced recurrences are likely to be due to relapse and some have
suggested treating true relapses for six weeks to one
year. 10 Most authorities suggest six weeks of therapy
with the realization that the optimal duration of therapy for this group of patients is controversial. An
alternative approach consists of intensive initia l treatment for IO to 14 days, followed by daily low-dose
nitrofurantoin (100 mg) or TMP-SMX (one half to
one tablet). Prophylaxis should be continued for up
to six months, then discontinued, and the patient
observed.
A cute complicated UTls are a third category of
infections; they are almost always associated with
underlying genitourinary tract or neurological disorders. Isolated organisms tend to be multiply
drug-resistant. Permanent eradication of the bacteriuria is unlikely, but the goal is to control symptoms. Initia l therapy ideally should be based on
sensitivity studies, but pending culture results, an
aminoglycoside antibiotic, that is, gentamicin, is an
obvious choice. Therapy for I 0 to 14 days is usually
adequate. Emergence of resistant organisms in this
setting is a probable event.
Asymptomatic bacteriuria represents a large
group of UTis with an incidence ranging from 1.2%
in pre-school girls to over 15% in women over age
60. 11 Certain groups are known to be at risk for
acquiring significant asymptomatic bacteriuria and

subsequent symptomatic UTI. Included are pregnant
women in the first trimester, women with diabetes,
preschool- and school-age girls, and those with a
previous history of urinary tract instrumentation .
About 5% of pregnant women will have asymptomatic bacteriuria at the first prenatal visit and 20% to
40% of these will develop acute pyelonephritis. 9 Assuming that acute renal infection in the mother contributes to prematurity and fetal mortality, treatment
should be initiated. The preferred agents are the penicillins, cephalosporins, nitrofurantoin, and shortacting sulfonamides (first trimester only). Treatment
will eliminate bacteriuria in 80% of these patients.
Some will have recurrence and for these patients,
nightly prophylaxis through term with nitrofurantoin
is recommended. The necessity to treat other groups
of patients with asymptomatic bacteriuria is less certain, especially elderly women in whom bacteriuria
tends to be recurrent even in the a bsence of underlying disease. Available evidence indicates that, in
adults, progressive renal damage due to UTI is an
uncommon occurrence in the absence of obstruction .10 Several attempts at eradication seem worthwhile. If bacteriuria recurs, genitourinary evaluation
is warranted. If no abnormalities are found, no further therapy is necessary in the elderly.
Catheter-related infections are the most common
hospital-acquired infections and the most frequent
causes of gram-negative bacteremia.•·11 Patients acquiring bacteriuria with short-term closed drainage
should be treated with an effective antibiotic for 7 to
IO days after the catheter is removed . Long-term
drainage represents a different problem. Patients on
long-term drainage are continuously infected but
usually do well. Antibiotics will not clear bacteriuria
permanently while the catheter remains in place.
Therapy is reserved for acute episodes of infection .
A scheme for the management of patients with
bacteriuria is given in the accompanying Figure. It is
meant to serve only as a guide for the practicing
physician a nd should be modified in light of future
improvements in the diagnosis, localization, and
therapy of UTis. Optimal therapy awaits a more
precise classification of UTis, the end result of which
will be a reduction in morbidity and mortality from
UTis, and a significant decrease in the cost of related
health care.

The figure is reproduced with permission from Urinary Tract
Infection and Its Management, Donald Kaye (ed).
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Intrascrotal Masses: Differentiation,
Diagnosis, and Management
STEPHEN N . ROUS, M.D.

Professor and Chairman, Department of Urology, Medical University of South Carolina, Charleston, South
Carolina

The differentiation of scrotal masses consists of
combining the basic principles of physical examination, particula rl y inspection a nd palpation, with a n
This is an a bstract of the lecture given by Dr. Ro us a t the
49th Annual M cG uire Lecture Series, December 3, 1977, at the
Medica l College of Virgini a, Richmo nd, Virginia .
A limited sup ply of book lets by Dr. Stephen N. Rous
e ntitled, "Intra-Scrota l Problems with Particular Reference to Pa lpatory Findi ngs," may be obtained fro m him, as long as they
remai n avail ab le, through the Department of Urology, M edical
U ni versity of South Carolin a, C ha rlesto n, SC 29403 .
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exact knowledge of the anatomy and pathology of the
scrotum a nd its contents. The correct diagnosis of
each of the nine common scrota l masses-epididymitis·, epididymo-orchitis, torsion of the spermatic
cord, hydrocele, scrotal hernia, spermatocele, varicocele, hematocele, and cancer of the testis-determines the treatment to be used, which can range from
masterly inactivity to surgical intervention. Obviously, experience plays its part a nd the opportunity
to exa mine scrotal masses should be an integral pa rt
of the education of the primary physician.
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Common Pediatric Problems: Hypospadias,
Enuresis, and Circumcision
JOHN H. TEXTER, JR., M .D.

Associate Professor, Division of Urology, Department of Surgery, Medical College of Virginia, Health Sciences
Division of Virginia Commonwealth University, Richmond, Virginia

Three topics of common pediatric interest from
the urologist's viewpoint are congenital hypospadias,
persistent enuresis, and complications of elective circumcision. None of these are usually life-threatening
in severity, yet each problem can be of profound
psychological importance and play an extremely important role in the child's subsequent development.
The least common of the three is a malformation
or incomplete formation of the male urethra and the
associated deformity of the foreskin and penile shaft
known as hypospadias. This condition results from
incomplete closure of the urethra in utero . Since the
urethra normally begins closing from the proximal
end of the penile shaft and progresses distally to the
glans, it is possible for the hypospadiac meatus to be
positioned at any location from the perineum to the
coronal sulcus. The timing of the arrest of the urethral closure will determine the location of the
meatus and the length of the deficient distal urethra.
Since the portion of the urethra which is not closed is
represented by fibrous tissue or what was destined to
be normal corpus spongiosum, this material is nonelastic and is represented by a fibrous band or tract.
When erection occurs, this tissue pulls down on the
penile shaft and produces the curvature of the penis
or ventral chordee seen in classical hypospadias . The
urethral closure is also responsible for the formation

Thi s is a n edited tran sc ript of th e lecture given by Dr. Texter
at the 49th Annual McGuire Lecture Series, December 3, 1977, at
the Medical Co llege of Virginia, Ri chmond , Virginia.
Co rrespo ndence a nd reprint requests to Dr. John H . Texter,
Division o f Uro logy, Box 176, Medical Co llege of Virginia, Richmond , VA 23298.
·
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of the normal prepuce. When hypospadias occurs,
the foreskin is incomplete ventrally, producing the
typical "dorsal hood" of preputial tissue seen in this
condition .
Over the years, numerous types of surgery have
been recommended to correct this malady. Often
these procedures were only partially successful, and
individual surgeons developed their own modifications of previously described techniques . A very effective method was used about 200 BC by the Greeks,
Helidous and Antius. They simply guillotined the
distal end of the penis at the level of the meatus. In
this maneuver, all three deformities were corrected;
the curvature was gone, the dorsal hood excised, and
the meatus was now at the end of the penis. The
stump end of the penis was then cauterized with a
red-hot iron which provided hemostasis and produced a swollen, knotty stub at the end of the penis
which occasionally resembled a glans penis. There
were also very few readmissions or requests for repeat
surgery.
Surgical techniques improved over the centuries.
In 1842, one of the first successful, planned hypospadias repairs was performed by Dr. John Peter
Mettauer in the western part of Virginia. With present-day techniques it is possible to completely repair
even the most severe degree of hypospadias and,
when healing is complete, to have a relatively normalappearing penis capable of normal micturition and
sexual function.
While the multitude of surgical repairs will not
be individually discussed, most severe degrees of hypospadias require corrective surgery performed in
stages. This often results in a child returning to the
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operating room at regular intervals over a period of
several years. This is undesirable from a financial as
well as a psychological standpoint. Fortunately, in
the mid-1950s, single-stage repairs became possible;
this not only decreased the psychological stresses on
the patient and family, but also produced excellent
cosmetic results. The tube graft repair for hypospadias was popularized by Ors. Devine and Horton
in Norfolk, Virginia. While the original technique has
been altered somewhat, the basic procedure is sound
and continues to produce excellent results in the
hands of many surgeons throughout the world. In the
late 1960s, the single-stage "flap" procedure was devised by Dr. Norman Hodgson which added another
useful tool to the urologist's armamentarium.
These new methods have changed our concept of
what is considered a satisfactory repair. In 1950, Dr.
Campbell's textbook, Urology, stated that if the hypospadias were mild and the meatus were located in
the distal part of the penile shaft, no attempt should
be made to correct the condition. If the patient had
"free urination and adequate insemination," any further surgical repair was "meddlesome"; however, today there is concern about the cosmetic appearance
as well as the functional capabilities of the penis. If
the chordee is mild and the meatus located distally, it
may still be desirable to correct these conditions and
position a new meatus on the tip of the glans penis.
This is now possible, using one of the new singlestage procedures; however, since both types of repair
require the use of excess skin which ideally can be
taken from the foreskin or dorsal hood, it is extremely important not to circumsize the child. If there
is any question about the possibility of subsequent
surgical correction at the time of birth, circumcision
should be postponed.
Enuresis

The second pediatric problem the urologist is
often asked to evaluate is far more common than
hypospadias. This is the problem of the persistent
bed-wetter. This problem is not unique to our country, but occurs throughout the world. It is interesting,
however, to note that the frequency differs greatly
from one country to another. For example, in the
United States there is an incidence of enuresis at age 5
of about 15% to 20%, whereas in Brazil the incidence
in this age group is close to 2%. This suggests that
social and environmental factors contribute to enuresis. With increasing age, enuresis generally becomes
less common so that in our country by age 10, only

5% of the children are enuretic and by age 15, only
1%. The reported incidence of 2% enuresis in military
recruits must be viewed carefully as the individual
may be influenced by the fact that bed-wetting is o'ne
of the criteria for military rejection. On the basis of
these statistics, it is valid for the family physician to
recommend to the family that treatment for enuresis
is not always necessary and if given enough time the
bladder will "mature and the child will outgrow his
or her bed-wetting."
Until the age of 3 years, enuresis or daytime
wetting is physiological and probably the result of
incomplete myelinization of the innervation. The age
of 3 years is purely an arbitrary cutoff point, but most
authorities agree that beyond this point, enuresis
should be considered to be either functional or organic. The majority of these enuretic children will
demonstrate a functionally decreased bladder capacity; however, under general anesthesia the bladder
volumes are within normal limits. In general, if the
wetting occurs only at night and there are no other
urologic symptoms, little is to be gained by doing an
extensive urologic evaluation. This impression is
borne out by the study of Dr. Tony Middleton of Salt
Lake City who studied the results of 216 enuretic
children who were completely evaluated and had only
enuresis. He concluded that the likelihood of identifying any major urologic abnormality was nil, although, if there were other symptoms or findings
such as urinary tract infection, diurnal enuresis, or
difficulty with urination, base line urologic evaluation
was helpful. According to this study, approximately
10% of the children required some type of surgical
repair.
It is interesting to note that many of these functional enuretic children came from a family in which
other members were enuretic. If both the mother and
father had enuresis, there was an 80% chance that one
of their children would be enuretic. Also, if the
mother or father developed their control at age 10,
then it was quite likely that their child would stop
wetting the bed at about the same age. Also, an
identical twin would be more likely to have enuresis
than a dizygotic twin.
There is a vast spectrum of recommendations
concerning the treatment for essential enuresis; however, most measures fall into one of three main categories.
1. Bladder training maneuvers and fluid restriction: Effort is directed to keep records of voiding
times and the volumes passed with each voiding. The
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patient is aroused during the middle of the night and
required to empty his bladder in order to keep the
bladder as empty as possible. Also, the youngster is
not allowed to drink any additional liquids, following
a set time of day such as after the evening meal or
before bedtime.
2. Drug therapy: Antispasmodics such as belladonna or propantheline bromide (Pro-Banthine) are
effectively used to increase functional bladder capacity. Other agents such as the tricyclic antidepressives
are prescribed for their altered sleep patterns and
their direct action upon bladder musculature. In the
group of antidepressive agents, the most popular one
at the present time is imipramine (Tofranil).
3. Waking devices: The sleeping youngster is
aroused from deep sleep by activation of some electrical device when urine leakage occurs. The urine
causes electrical contact to occur and completes a
circuit which in turn sets an alarm, electrical stimuli,
or flashing lights. The waking devices are said to be
very popular in England and are reported to be quite
effective in terminating enuresis. In the United States
and Canada more emphasis has been placed upon the
bladder training program and drug therapy. Both
techniques are reported to be effective in 65% to 80%
of enuretic patients.
Circumcision
Today, circumcision is the second most frequently performed operation on the male. While it is
often performed for religious purposes and less often
for strict urologic indications, the largest number of
circumcisions are done for hygiene or simply as a
routine procedure. Dr. Julien Ansell at the University
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of Washington in Seattle evaluated all the circumcisions performed in the University Hospital during a
10-year period of time. It is of note that of 5,882 male
births, 5,521 or 94% were circumsized before they left
the hospital. Of the remaining 361 male infants who
were not circumsized, 22 were denied the operation
because of some degree of hypospadias . This correlates well with the reported incidence of hypospadias
of about 1 per 267 male births.
About half the circumcisions were done with the
Gomco® clamp and the remaining half performed by
the Plastibell® apparatus. The overall complication
rate from routine elective circumcision was slightly in
excess of 1%. This was most often due to hemorrhage
occurring equally often with the Gomco® clamp and
the Plastibell®. Most bleeding problems were easily
managed by application of an adrenaline (1-1,000)
soaked sponge applied to the area of bleeding (25 out
of 59 patients were successfully handled by this measure). The others required placement of a suture or
ligature to provide hemostasis. Infections were uncommon, occurring in less than 0.4% of patients and
were generally managed with local measures such as
cleaning and soaks. Only four patients, all of whom
had Plastibell® circumcisions, required systemic antibiotics. Nine patients had wound-healing problems
such as dehiscence and denudation of the penile shaft
skin. Eight of these patients had Gomco® clamps
used for the circumcision. In general, it was concluded that circumcisions can be performed routinely
with a low complication rate and those complications
that do occur are relatively easy to manage. The type
of clamp used for the operation does not appear to
make a significant difference.

Management of Carcinoma of the Kidney and
Urinary Bladder
WARREN W. KOONTZ, JR., M.D.
Professor and Chairman, Division of Urology, Department of Surgery, Medical College of Virginia, H ea/th
Sciences Division of Virginia Commonwealth University, Richmond, Virginia

CARCINOMA OF THE KIDNEY

Tumors of the upper urinary tract constitute 1%
to 2% of all cancers, and each year 11,000 new cases
are diagnosed in the United States. Approximately
half of these patients have metastatic disease at the
time of diagnosis. Hypernephroma, or renal cell carcinoma, was first described in 1863 by Grawitz. These
tumors arise from tubular epithelial cells and are
correctly termed renal cell carcinoma or renal cell
adenocarcinoma. There is evidence that further identifies the cell of origin as being from the proximal
convoluted tubular epithelium. There does not appear to be a specific racial or ethnic incidence although it occurs three times more often in men than
in women. Few epidemiological studies of this disease
have been undertaken, although there is some association between the use of tobacco and an increased
incidence of renal cell carcinoma. The classical triad
of hematuria, pain, and a palpable mass are late
findings with a poor prognosis which occurs in 10%
of the patients and usually represents metastatic disease. Forty percent of the patients may have hematuria or other urinary complaints. Local effects of the
tumors are hematuria, pain, and a flank mass, but the
presenting symptoms may include a varicocele in the
male which is produced by direct pressure of the
tumor on the spermatic vein or because of stasis

caused by an obstructing tumor thrombus in the vena
cava. Systemic toxic effects such as hyperpyrexia may
be of an intermittent or variable nature. Anemia or
abnormal liver chemistries may also be present.
Erythrocytosis, hypertension, and hypercalcemia
may also be manifest.
Once a renal mass is found, a number of procedures can be followed in order to evaluate the patient
before surgery. These include the use of intravenous
excretory urography, retrograde pyelography, nephrotomography, renal angiography, and venacavography, along with sonographic examination of renal
masses and the evaluation of renal masses by the use
of computerized axial tomography.
The staging classification developed by Robeson
is probably the most widely accepted: Stage I-tumor confined within the kidney; stage 2-perirenal
fat involvement confined within Gerota fascia; stage
3-a. gross renal vein or inferior vena cava involvement, b. lymphatic involvement, and c. vascular
and lymphatic involvement; stage 4-a. adjacent organs other than the adrenal involved, and b. distant
metastases. Renal vein involvement without perinephric involvement or lymphatic spread does not
seem to alter the prognosis at 5-10 years where lymphatic involvement is an ominous sign.
Treatment

This is an edited transcript of the lecture given by Dr. Koontz
at the 49th Annual McGuire Lecture Series, December 4, 1977, at
the Medical College of Virginia, Richmond, Virginia 23298.
Correspondence and reprint requests to Dr. Warren W.
Koontz, Division of Urology, Box 176, Medical College of Virginia, Richmond, VA 23298.
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Surgical removal of the tumor for cure is the
basic management of the patient with hypernephroma. The single, most significant advance in
technique and its influence on survival were pointed
out in 1968 by Robeson, who used the combination
of early ligation of the renal artery and vein, complete
MCV QUARTERLY 14(2): 80-82, 1978
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removal of the perinephric envelope, and surgical
extirpation of the lymphatic field. Caution in handling of the renal vein is important, especially if there
is tumor involvement of the veins, as portions of
renal vein tumor may break off and cause acute pulmonary embolization.
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therapy for them is total removal of the kidney and
renal pelvis with removal of the entire ureter and a
cuff of bladder. For those people who have undergone only partial removal of the ureter, recurrence in
the stump of ureter has been high .
BLADDER CANCER

Preoperative Radiation
Several investigators have advocated the use of
preoperative radiation in the management of renal
cancer, but random clinical trials to date have not
shown that this has improved long-term survival. In
certain patients, however, a preoperative course of
radiotherapy of 3,000-4,000 rads to the kidney in four
weeks has markedly decreased the vascularity of the
tumor. There is some evidence that postoperative
radiotherapy may have a beneficial effect on survival
statistics, especially if there has been extracapsular
invasion and tumor has been left behind.
Chemotherapy
The use of chemotherapy in the management of
metastatic renal carcinoma has proven particularly
disappointing. Good results have been quoted by
some investigators with the use of medroxyprogesterone (Provera) 100 mg t.i.d . and a number of other
chemotherapeutic agents singly or in combination.
Special Management Problems
Involvement of the renal vein and vena cava are
of interest because of the possible use of extracorporal circulation in order to approach the patient
with tumor thrombus in the renal vein, the vena cava,
and the atrium of the heart.
Carcinoma arising in a solitary kidney provides
a real therapeutic dilemma. Procedures such as partial nephrectomy in situ, bench surgery with the removal of the kidney, perfusing the kidney for preservation, surgical excision of the tumor with repair of
the kidney and autotransplantation back into the
patient, and total extirpation with homotransplantation at a later date have all been used.
Approximately 12% of upper urinary tract malignancies are from renal pelvic tumors. These are
often transitional cell carcinomas, but a few are of the
squamous cell variety. The diagnosis is usually based
on the appearance of a filling defect on intravenous
urography or retrograde pyelography. A differential
diagnosis from a nonopaque stone or blood clot may
be difficult. As these tumors tend to be multiple, the

Carcinoma of the urinary bladder accounts for
4% to 5% of all new cancers. Approximately 30,000
new cases of bladder cancer are found in the United
States each year resulting in over 9,500 deaths. The
incidence is three times more prominent in men than
in women and four times more common in whites
than in non-whites. Age distribution reveals a peak in
patients 75-84 years of age, and 80% of these tumors
occur after age 50.
The known and suspected causes of bladder cancer are grouped into four categories: 1) Industrial
chemicals; 2) metabolites of foodstuffs; 3) tobacco
tar; and 4) chronic mechanical irritation and infection.
All but 3% to 4% of bladder tumors originate in
the transitional cell epithelium . Transitional cell carcinoma of the bladder occurs in approximately 90%
of the patients, with squamous cell carcinoma accounting for 6% to 7% and adenocarcinoma 1% to
2%. Transitional cell carcinomas may be very small
and papillary in character but may be multiple, large
and sessile tumors; the surface may be intact or ulcerated, crusted, and bleeding. Squamous cell cancer, on
the other hand, is usually flat, ulcerated, and sometimes necrotic; adenocarcinoma appears grossly as
transitional or squamous and must be differentiated
microscopically.
Diagnosis
Painless, gross hematuria is found in 75% to 85%
of the patients presenting with carcinoma of the bladder. As the tumor enlarges, other symptoms such as
frequency, urgency, dysuria, and decrease in caliber
or force of the urinary stream may be present. These
symptoms may be secondary to infection of the bladder or may be irritations caused by the tumor. As the
tumor progresses, the suprapubic pain and a palpable
mass may become prominent, these being associated
with obstructive uropathy and uremia.
The diagnosis is made at the time of cystoscopy
when a tumor is seen and biopsies can be obtained. It
is important that a rectal and bi-manual examination
be done to assess the size of the mass. A palpable,
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hard, indurated mass is usually a sign of an advanced
tumor and a poor prognosis.
Intravenous urography is an important step in
the assessment of the patient with bladder cancer.
The urogram will indicate the functional status of the
kidneys and the possibilities of ureteral obstruction.
By using triple-phase contrast studies of the bladder,
one can ascertain fixation of the bladder wall and the
possibility of invasion. If this is combined with pelvic
arteriography in conjunction with perivesical and intravesical gas or with computerized axial tomography, a better evaluation of the size of the tumor may
be found.
Grading and Staging

All tumors can be graded histologically based on
the degree of cellular anaplasia. Grade I or welldifferentiated tumor has a much better prognosis
than a grade III or IV or poorly differentiated tumor.
Staging in the United States has usually been by the
A, B, C, D classification of Jewett and Strong, and
Marshall. Recently the TNM (Tumor, Nodes, Metastasis) classification of the International Union
Against Cancer has been publicized in order to get
physicians in the United States to switch to that
classification of all tumors. In general, however, a
stage 0 tumor is one that is localized only to the
mucosa; stage A is limited to the submucosa, and
stage B, indicates that the tumor has invaded the
bladder muscle but is less than half-way through the
bladder wall. Stage B2 tumors extend through the
bladder muscle but do not invade the perivesical fat,
and stage C indicates perivesical fat involvement or
involvement of the capsule of another organ. Stage
D, tumors are those that have spread to the regional
pelvic lymph nodes or have invaded the pelvic wall or
rectus muscle or both. Stage 0 2 tumors exist when
the tumor has spread beyond these limitations and is
outside the pelvis and the immediate bladder area.

Metastases occur most often to the regional lymph
nodes, lungs, liver, and bone.
Treatment

The treatment of the patient with a superficial
tumor is usually by means of endoscopic surgery with
transurethral resection. Careful follow-up examination with repeat cystoscopies every three months for
one year, and every six months for five years, and
every year thereafter are necessary in order that any
residual or recurrent tumors may be promptly found
and the appropriate treatment instituted. For the patient with multiple recurring tumors, the use of intravesical therapy (ThioTepa), partial or total removal
of the bladder, or radiation are possible therapeutic
choices. For the patient with invasive transitional cell
carcinoma, endoscopic procedures are not adequate.
One cannot endoscopically tell the degree and extent
of the tumor, therefore, an open surgical procedure
with remova l of the entire tumor or radiation therapy
is indicated. It would appear as of this writing, that
the best results are obtained from preoperative radiation followed by open surgical extirpation of the tumor, usually a radical cystectomy with urinary diversion. There is some discussion about whether 2,000
rads in one week , 4,000 rads in 4 weeks, or 4,500 rads
in 6 weeks followed by either immediate or delayed
cystectomy is best.
Chemotherapy

Long-term survival is rare once the tumor has
spread beyond the confines of the bladder. One
means of destroying metastases, however, may be
through the use of combinations of chemotherapeutic
agents. Drugs used in the management of patients
with transitional cell carcinoma of the bladder have
been 5-fluorourocil, bleyomycin, adriamycin, cyclophosphamide (Cytoxan) and the cis-platinum compounds.

Testicular Carcinomas and Carcinoma of the
Prostate
PAUL F. SCHELLHAMMER, M.D.
Associate Professor of Urology, Eastern Virginia Medical School, Norfolk, Virginia

TESTICULAR CARCINOMAS

Incidence
Testicular neoplasms are relatively rare with approximately two new cases per 100,000 male population occurring per year. The peak occurrence is
between the ages of 20 .and 40. Because of their
highly malignant characteristics testicular neoplasms
must be treated aggressively if cure is to be achieved.
Etiology
The most significant etiologic factor is the predisposition for the occurrence of carcinoma in the
cryptorchid or undescended testicle. The cryptorchid
testis is at 40 to 50 times the risk of the normal scrotal
testicle for developing a cancer; various theories for
this predisposition to malignancy have been proposed. The most likely is that the cryptorchid testicle
is inherently abnormal (a very strong argument also
to explain its failure to descend) and therefore provides a fertile ground for neoplastic change.
Histology
Testicular tumors may be divided into neoplasms of germ cell origin (arising from the spermatogonia within the seminiferous tubules) and of nongerm cell origin (arising from the supporting Leydig
and Sertoli cells). The latter constitute only 5% of all
testicular tumors.
For purposes of histology and treatment regimens the germ cell tumors are divided into the semiCorrespondence and reprint requests to Dr. Pa ul F. Schellhammer, Hague Medical Center, Suite 100, 400 West Brambleton
Avenue, Norfolk, VA 23510.
·
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nomatous tumors which are most common, constituting approximately 60% of all testicular tumors,
and the non-seminomatous tumors constituting the
remaining 35% of tumors. The non-seminomatous
tumors consist of embryonal carcinoma, teratocarcinoma, teratoma, or choriocarcinoma. Rarely do each
of these types exist in absolutely pure form; most
nonseminomatous tumors combine the elements of
embryonal and teratomatous carcinomas and these
may have elements of choriocarcinoma as well. With
the exception of pure choriocarcinoma, a distinctly
rare entity comprising less than 1% of tumors, the
treatment regimen for the nonseminomatous tumors
is identical to and independent of the percentage of
each histologic type that constitutes the mixed tumor.
Diagnosis:
All testicular masses must arouse suspicion of
carcinoma and some swellings such as testicular hematomas, orchitis, and epididymitis may cause induration difficult to distinguish from a tumor diagnosed only by inguinal exploration and biopsy.
Treatment
When a testicular mass is suspect of carcinoma,
it must be explored through an inguinal incision. A
rubbershod or umbilical tape is used to obstruct the
venous return and therefore reduce or eliminate embolic dissemination during manipulation of the testicle. If there is some doubt about the diagnosis, the
testicle is isolated with towels, and a biopsy and a
frozen section are performed prior to orchiectomy
and removal of the cord. The testicle must never be
biopsied through the scrotum, either by incision or by
needle aspiration; by doing so an entirely new nodal
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chain for metastases is established. The testicle drains
to the para-aortic nodes, the scrotum to the inguinal
nodes. If the tumor cells seed in the scrotal incision,
which can easily occur, then the entire inguinal chain
is at risk for embolic metastases.
The diagnosis of testes tumors is too often delayed for a number of reasons. Routine and careful
bi manual examination of the testes is often omitted in
routine examinations. Furthermore, patients who
note testicular masses are often reticent to present
their complaints to a physician because of embarrassment, or fear of association with venereal disease.
Metastatic evaluation. Once a diagnosis is made
a number of radiologic studies, serum studies, and
urine studies are warranted to stage the neoplasm and
identify areas of metastases. The chest represents a
common area of distant metastases and should be
evaluated not only by anteroposterior and lateral xray, but by pulmonary tomograms . Lesions are frequently bilateral and multiple. The primary route of
drainage of the testicular lymphatics is to the paraaortic and paracaval nodes between the superior mesenteric and the inferior mesenteric arteries. Crossover drainage does occur and is most frequent from
the right side to the left. Bipedal lymphangiography is
of importance in identifying spread to the retroperitoneal nodes . Para-aortic and paracaval nodes
are well visualized as is, frequently, the supraclavicular node. Intravenous pyelogram also assesses the
retroperitoneum by evaluation of renal and/ or
ureteral deviation, compression, and deformity.
Computerized axial tomography (CT) scanning and
ultrasound studies can be used to delineate retroperitoneal masses precisely and may be used as
noninvasive techniques to follow these masses periodically during the course of chemotherapy or radiotherapy to evaluate treatment.
Staging of testes tumors is as follows:
Stage A: Tumor limited to testes, that is, no metastases.
Stage B: Tumor present in testes with metastases
limited to regional nodes, that is, paraaortic nodes below diaphragm.
Stage C: Tumor present in testes with metastases
beyond regional nodes, that is, metastases to scalene node, lung, bone, liver,
and so forth .
Seminomatous tumors. These neoplasms are
characteristically very radiosensitive. Radiotherapy
constitutes the main method of treatment and rarely,
if ever, is surgery indicated. If the tumor is Stage A

(negative lymphangiogram and pulmonary tomograms ), radiation is given in the dose of 2,500 R to
the ipsilateral-iliac nodes and to the para-aortic
nodes bilaterally to the level of the diaphragm.
If the tumor is Stage B (evidence of nodal involvement on lymphangiogram), the fields are extended so as to include the mediastinum and bqth
supraclavicular areas, and the infradiaphragmatic
area is treated to 3,000 R. The 5-year survival rate for
patients with Stage A tumors, so treated, ranges
around 95%. If the tumor is Stage B (evidence of
positive para-aortic nodes), the 5-year survival rate
will range around 80%.
If the tumor is Stage C (evidence of pulmonary
visceral or osseous metastases), radiation therapy
may be given to these areas of metastatic involvement
if they are relatively isolated, that is, one or two
pulmonary nodules in one lung lobe. If disease is
more diffuse, however, a radiomimetic chemotherapeutic agent, either chlorambucil (Leukeran) or cyclophosphamide (Cytoxan) is used . Five-year survival rates for Stage C tumors range between 40% and
50%.
The only indication for surgery for seminomatous tumors arises with the failure of what has
been diagnosed as seminoma to respond satisfactorily
to radiotherapy . In such a case one must suspect the
presence of non-seminomatous elements, and surgery
with excisional biopsy will eliminate the lesion, confirm a change in histology, and dictate a change in
treatment to that used for non-seminomatous neoplasms.
Non-seminomatous tumors. There is significant
controversy as to the optimal management of nonseminomatous tumors with North American urologic
centers applying surgery, and European centers employing radiation therapy as the primary modes of
treatment of the retroperitoneal area . Non-seminomatous tumors are much more difficult to control with radiation than the seminoma and therefore radiation failures are more common .
In the United States a non-seminomatous neoplasm is approached as follows: if the tumor is Stage
A, a retroperitoneal node dissection is undertaken; if
lymph node dissection reveals no evidence of histologic metastases to the nodes, no further treatment is
undertaken ; and if the nodes are positive, chemotherapy is administered as the tumor is pathologically Stage B.
If the tumor is Stage B, a node dissection is again
performed and chemotherapy instituted postopera-
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tively. If nodal dissection is incomplete or there is
tumor spillage, radiotherapy postoperatively to the
retroperitoneal area is recommended. Chemotherapy
is administered for two years after the last evidence of
clinical disease is noted.
If the tumor is Stage C, chemotherapy is instituted and if clinically measurable metastatic disea se
regresses, a node dissection is then considered.
Five-year survival rates for Stage A, non-seminomatous tumors range from 85% to 90% (the pathologist is not always 100% accurate and may have
missed microfoci in the excised lymph nodes and/ or
metastases may have skipped the retroperitoneal
nodes and dissiminated distantly without nodal involvement). Five-year survival rates for Stage B disease are 60% to 70% and for Stage C , 25% to 30%.
Tumor markers. Until recently, 24-hour urinary
choriogonadotropin was measured in patients with
testicular tumor in an effort to identify those with
choriocarcinoma which as a functioning cell would
produce choriogonadotropins detectable in the urine.
The assay used is a biological one and has all the
inherent difficulties of bioassays.
A serum radioimmunoassay has been developed
to overcome this difficulty. It measures the B chain of
human choriogonadotropin (termed Beta sub unit)
and is very sensitive and specific. Any elevation in the
male is abnormal and indicates the presence of functioning tumor cells.
Alpha-fetoprotein is a protein produced by the
fetus, but its production ceases and levels fall to
nanogram marks soon after birth. Testis carcinoma
cells may revert to the metabolic machinery of the
fetal cell and produce alpha-fetoprotein , causing increased serum levels. Like the Beta sub unit, elevated
alpha-fetoprotein identifies the presence of active tumor.
Tumor markers are sensitive indicators of residual microfoci of disease long before any evidence of
clinical or radiologic disease may appear. Active chemotherapy must continue until tumor markers are
reduced to and remain within normal levels .
CARCINOMA OF THE PROSTATE

Incidence
The incidence of ca rcinoma of the prostate is
steadily increasing; at the present time it is the most
common genitourinary malignancy and the second
leading cause of death from cancer among males
in the United States. Its incidence of 60 new cases/
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100,000 population and 20 deaths/ 100,000 population per annum is exceeded only by carcinoma of
the lung. The incidence of carcinoma of the prostate increases with age, and autopsy studies have
revealed it in 50% to 80% of males who have survived
to age 80. Thus, we can a nticipate that with greater
longevity the diagnosis of prostatic carcinoma will
be made more frequently and the problems of
treatment of a malignancy in an aged population
will be of increasing concern .

Etiology
No specific carcinogen has been identified as the
cause of prostate cancer. The most likely inciting
event at present is a change in the hormonal milieu
which occurs as a natural consequence of aging. The
nature of the change and the hormone fluctuations
involved are as yet unidentified.

Anatomy and Histology
The prostatic glandular elements can be divided
into two major sectors-the inner periurethral glands
and the peripheral tuboalveolar glands which are
connected by long ducts to the prostatic urethra. The
periurethral glands are those which most frequently
give rise to benign hypertroph y and the peripheral
tuboalveol a r glands to adenocarcinoma of the prostate.

Natural History
Carcinoma of the prostate is a neoplasm with
varied growth characteristics and degrees of malignancy. The tumor may be rapidly metastatic and
cause death within one to two years or it may be
slowly growing, metastasizing only five to ten, or
even fifteen , years after discovery of the primary lesion ; another five or more years ma y pass before the
metastases become life-threatening. This variability
makes it difficult to assess the efficacy of therapy, and
makes it necessa ry to follow patients for ten to fifteen
years after initiating treatment in order to judge its
value. The reason for this is that, given a tumor with
a relatively slow-growing and benign course, one cannot state whether prolonged survival is based on the
treatment administered or the low biologic potential
of that tumor. Unfortun a tely, at the present time
there are few characteristics, other than the grade of
anaplasia, that can be measured to identify at the
time of diagnosis which tumors will follow a benign
course from those which will not.
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Diagnosis
While a high index of suspicion may be generated by induration felt on digital rectal examination,
carcinoma of the prostate must be ultimately diagnosed by histologic proof of malignancy. A number
of other causes for induration of the prostate include
prostatic calculi, granulomatous prostatitis, nodular
prostatic hypertrophy and, more rarely, tuberculous
granulomas. Once a suspicious area of in duration or
nodularity is identified a transperineal or transrectal
needle biopsy employing the Vim-Silverman needle is
used to obtain tissue for histologic examination.
Other warning signals in the elderly male of
prostatic cancer include the onset or recent exacerbation of low back pain, possibly a reflection of
osseous metastases; the presence of sciatic pain, possibly a reflection of sciatic nerve impingement by
massive retroperitoneal lymphadenopathy secondary
to metastases; and the rapid progression of bladder
outlet obstruction which can be identical to that seen
with benign prostatic hypertrophy (BPH).
Radiographic identification of carcinoma of the
prostate is facilitated by the characteristic radiodense
or osteoblastic lesions most frequently found in the
pelvic bones and the lumbosacral spine. These may
be identified on routine skeletal survey, but more
early identification is provided by the technetium 99
phosphorous bone scan which identifies metastases
prior to radiographic skeletal changes. (It has been
shown that more than 50% of the bone must be
destroyed or replaced by malignancy before a routine
skeletal survey becomes positive). Intravenous pyelography may demonstrate obstruction at the ureterovesical junction secondary to prostatic malignant
growth and, specifically, involvement of the seminal
vesicles. Also the ureters may be displaced by retroperitoneal metastatic adenopathy.
Biochemical or serum abnormalities occur with
prostatic carcinoma. Serum acid phosphatase represents· the most characteristic and distinct abnormality; in essence, it is a tumor marker. It can frequently
be used to identify the presence of metastatic disease,
and its levels may be followed as a means of monitoring treatment; however, it is not a specific test as
acid phosphatase may be elevated in a number of
other diseases such as pulmonary embolism, muscle
necrosis, Gaucher disease, and osteosarcoma, to
mention a few. It is also not a very sensitive marker as
diffuse metastases may be present in the face of a
normal acid phosphatase. The recent development of
a radioimmunoassay for measurement of prostatic

acid phosphatase offers significant advantages for tumor staging, and follow-up. The immune assay is
specific for the prostatic fraction of acid phosphatase
and is sensitive to extremely minor changes in serum
levels of the enzyme. Elevation of alkaline phosphatase is a reflection of bony destruction and repair.
Serum calcium may be elevated as a result of. extensive osseous metastases.
Treatment
Many methods of treatment are used either individually or in combination. Transurethral resection
of the prostate is used to relieve obstruction. This is
obviously palliative and relieves symptoms but does
nothing to stem or alter the growth of the neoplasm.
Radical prostatectomy, namely the total removal of
the prostate gland and the seminal vesicles, is performed with the intent to cure by removal of all
neoplasm. Curative radiation therapy delivered from
a linear accelerator or cobalt source is directed at the
prostate and often the pelvic lymph nodes as well.
Interstitial implantation of radioactive seeds is used
in an effort to deliver high local doses.
Treatment is based on the staging of the disease
at the time of presentation: Stage A-carcinoma entirely unsuspected on physical examination, or on
serum chemical or radiographic examination but
which is found incidentally on pathologic examination of the prostate excised for presumed BPH, that
is, in the transurethrally resected prostatic chips or
the prostate enucleated by an open technique. Stage
B-tumor confined to the prostate gland on physical
examination specifically without lateral or seminal
vesicle extension; Stage C-tumor locally confined to
the pelvis but demonstrating lateral extension and
seminal vesicle invasion; Stage D-metastases to
lymph nodes, bone, lung, and so forth.
Management of Stage A depends to a large extent on the patient's age, the grade of lesion, and the
extent of the involvement. When only microfoci of
well differentiated neoplasm are present, it is reasonable to pursue no further treatment. If the tumor is
more extensive or poorly differentiated, treatment is
as outlined for Stage B.
For Stage B, either radical excision of the prostate and seminal vesicles (radical prostatectomy) or
treatment with external beam radiotherapy or interstitial implantation of radioactive sources (1-125
seeds) may be employed. The advantages of radiotherapy are the inclusion of the periprostatic tissue
(and thereby hoped-for sterilization of microscopic
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extensions outside the prostate) and avoidance of the
side effects of surgery, namely universal impotence
and a 10% to 20% incidence of incontinence.
The survival rates for Stage 8 carcinoma of the
prostate are approximately 75% at five years, 45 % to
50% at ten years, and 25% to 35% at fifteen years.
In Stage C carcinoma of the prostate, extension
beyond the confines of the prostate and seminal vesicles usually makes cure by radical prostatectomy
highly unlikely; therefore, radiation therapy , either
external beam or interstitial seeds, constitutes the
mainstay of treatment. Occasionally it is also necessa ry to relieve prostatic obstruction by transurethral
prostatectomy either before treatment or immediately afterwards. Five- and ten-year survival rates for
Stage Care approximately 45% and 30% respectively.
The philosophy for treatment of Stage D carcinoma of the prostate varies throughout the country .
It is our policy to await the appearance of symptoms
prior to the institution of therapy. Cure of Stage D
prostatic neoplasm has not been documented, and
therefore palliation of symptoms, and prolongation
of survival remain the primary objectives of treatment. Conditions warranting treatment include systemic symptoms such as weight loss, fatigue, weakness , bone pain, ureteral obstruction, and bone
marrow replacement as evidenced by anemia.
Hormonal manipulation (estrogen or orchiectomy) is the mainstay of treatment for metastatic carcinoma of the prostate . Dramatic relief from
pain and regression of metastases, and at times complete disappearance of the primary prostatic lesion,
follow the administration of hormones, or castration.
The administration of estrogens works via the negative feedback system whereby high-estrogen doses
suppress luteinizing hormone (LH) and follicle-stimulating hormone (FSH), both of which are pituitary
trophic hormones stimulating the testes to produce
testosterone . Orchiectomy removes the source of
androgen production. It is felt at the present time that
either one of these modes is equally effective and can
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be expected to produce regression in approximately
80% of patients with prostate carcinoma. There is no
documented advantage from using both methods,
that is, estrogen plus orchiectomy as opposed to either one or the other alone, nor unfortunately is a
second regression seen with any frequency by applying one of these modes when a relapse occurs after
the institution of the other.
Estrogens have certain distinct disadvantages; an
orally ingested pill is required daily , nausea can occur, as can gynecomastia and other secondary sex
changes . Of greater significance is data demonstrating an increased incidence of death from cardiovascular disease, n a mely fluid retention, pulmonary edema,
and congestive heart failure in patients receiving estrogen therapy. Orchiectomy, a simple surgical procedure that can be performed under local anesthesia ,
avoids these secondary effects of estrogen treatment.
Other forms of hormonal ablation include adrenalectomy and hypophysectomy, but these are rarely
used and have not been consistently successful in
offering extended palliation.
Local radiation therapy to painful osseous lesions may significantly relieve discomfort. Radiation
is reserved for treatment of well-localized areas of
painful metastases.
Cytotoxic agents have just come under investigation in clinical trials and hold some promise for treatment of estrogen failures . Investigation of certain
cytotoxic agents linked to hormones (Estracyst =
estrogen + nitrogen mustard ; Leo = prednisone +
chlorambucil) suggests that cytotoxic agents may be
delivered within the prostatic cancer cell by steroid
carriers which attach to hormone receptors . Other
agents which depend on the acid phosphatase enzyme
for cleavage to the active form are also in developmental stages .
REFERENCE
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Adenocarcinoma of the Prostate: The
Rationale and Role for Radiotherapy in its
Management
TAPAN A. HAZRA, M.D.

Department of Radiology, Division of Radiation Therapy and Oncology, Medical College of Virginia, Health
Sciences Division of Virginia Commonwealth University, Richmond, Virginia

Until recently the treatment of carcinoma of the
prostate was limited either to radical prostatectomy
by the perinea! or retropubic route, or to hormonal
manipulation. Approximately 5% of all patients with
this disease are suitable candidates for radical surgery. Hormonal manipulation is palliative in nature
and is generally used when there is evidence of metastatic disease (in about 50% of patients). There thus
remains a group of patients (40% to 45%) in whom
the disease is localized, yet too extensive for surgical
treatment, for whom definitive radiotherapy can play
a major role.
Pre-treatment Evaluation
Once the histological diagnosis of carcinoma of
the prostate has been made it is desirable to delineate
the exact extent of disease in order to provide certain
guidelines for optimal management and for predicting prognosis. In an attempt to evaluate the various
diagnostic procedures, we at the Medical College of
Virginia are conducting an ongoing study where all
patients with clinically localized prostatic carcinoma
undergo the following work-up:
1. Laboratory Studies
a) WBC, hematocrit, platelets
b) Total and prostatic fraction of acid phosphatase (blood is obtained either prior to
or at least 24 hours after rectal examination).
Correspondence and reprint requests to Dr. Tapan A. Hazra,
Box 752, Medical College of Virginia, Richmond, Virginia 23298.
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c) Alkaline phosphatase and BUN.
d) Bone marrow biopsy for histological examination, and radioimmunoassay for
prostatic acid phosphatase.
2. Radiological Studies
a) Chest x-ray
b) Intravenous pyelography
c) Bipedal lymphangiogram
d) 99 m Tc Labeled di-phosphate bone scan
Radiation Therapy
Although the use of ionizing radiation in the
treatment of carcinoma of the prostate was first reported in 1911 by Pasteau, 1 the majority of reports
have appeared within the last ten years. In a recent
comprehensive review of the subject Ray and his
colleagues 2 have documented clinical studies which
collectively report on 880 cases in which external
beam irradiation was the primary mode of treatment.
They have concluded "that potentially tumoricidal
dosage of irradiation can be delivered to the prostate
with relative safety and in general the initial response
of the local tumor to irradiation in survival rates at
five years were encouraging."
Results

Local. In general , the reports of various authors
support our experience that 70% to 80% of patients
show marked resolution of the disease within six
months on clinical examination. We do not, at the
present, recommend post-treatment prostatic
biopsies as a routine procedure.
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Survival. On reviewing the results of various investigators dealing with the definitive treatment of
adenocarcinoma of the prostate with megavoltage
irradiation therapy, one finds that the five-year survival rate varies from 60% to 70% and the ten-year
survival rate varies from 30% to 40%. Ray and his
colleaguess from Stanford University have reported
the results of treatment for two clinical groups of
patients based upon the extent of the disease as determined by digital examination . In one group of patients the disease was limited to the prostate and this
group of patients had a 71 % and 41 % survival rate at
five and ten years respectively. In the other group of
patients the disease had extracapsular extension and
this group of patients had 41 % and 31 % survival rates
at five and ten years respectively. Hillaris and his
colleagues 4 from Memorial Hospital have reported
that all patients with intracapsular diseaself i. T2 ,
and Ts) and negative lymph nodes were alive and free
of disease at five years while disease-free survival
decreased to 70% in patients with extracapsular disease and negative nodes or in patients with intracapsular disease with positive nodes. Only 50% of
patients with extensive local disease (Ts and T 4 ) and
positive nodes were alive without evidence of disease
at five years. It has been my experience that dissemination of disease is more frequent in patients with a
large primary tumor, with a high-grade tumor , and in
the presence of histologically positive lymph nodes.
In addition, there is rapid systemic dissemination of
the disease once the para-aortic lymph nodes are
involved.
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Present Area of Clinical Investigation

The major cause of failure of definitive radiotherapy in carcinoma of the prostate is the spread of
tumor, outside the high dose of radiation field, either
to the lymph nodes or to the bones. It is generally
accepted that young patients (below 65 years), patients with a high-grade tumor and with diffuse involvement of the prostate gland (multiple chips involved, post-transurethral resection of the prostate)
have a poor survival rate even when they present with
early (stage A) disease. It remains to be seen whether
definitive radiation therapy in this select group of
patients with stage A carcinoma of the prostate will
alter the natural history and provide an improved
survival rate.
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Management of Acute Glomerulonephritis
DONALD OKEN, M.D.

Professor and Chairman, Division of Nephrology, Medical College of Virginia, Health Sciences Division of
Virginia Commonwealth University, Richmond, Virginia

Glomerulonephritis is responsible for over one
half of all cases of end-stage chronic renal failure
and, in its most fulminant form, is a cause of acute,
irreversible renal failure. Electron microscopy and
immunofiuorescent studies together with newly recognized clinical associations have revealed a wide
variety of histologic subgroups and myriad etiologies
for what was once regarded as a single, simple entity.
The addition of electron microscopy has lent an entirely new dimension to the delineation of glomerulonephritis subtypes and offers a more reasonable approach to the search for treatment of these subtypes.
It is, after all, not unreasonable to suppose that different etiologic factors and host responses are involved in the various pathologic lesions so clearly
defined on electron microscopy. Immunofiuorescent
studies identify the presence of immune globulins and
complement components in glomerular lesions and
aid in recognition of their localization sites; they may
reveal the contribution of fibrin deposition or specific
antigens in the pathogenesis of glomerular involvement.
Most, if not all, forms of glomerulonephritis are
acknowledged to be the result of immunologic processes, and many can be mimicked by immunologic
manipulations in laboratory animals. A growing
body of research data . has incriminated circulating
immune complexes, activation of the complement
cascade and the coagulation system, antibodies directed specifically against the glomerular basement
This is an abstract of the lecture given by Dr. Oken at the 49th
Annual McGuire Lecture Series, December 4, 1977, at the Medical
College of Virginia , Richmond, Virginia.
Correspondence and reprint requests to Dr. Donald Oken,
Chairman, Division of Nephrology, Box 197, Medical College of
Virginia, Richmond, VA 23298.
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membrane, proteolytic activity of leukocytes, and
other phenomena in the mediation of particular types
of glomerular injury. In experimental animals, at
least, manipulation of the antigen: antibody ratio or
depletion of complement and/ or polynuclear leukocytes may blunt the severity of, or prevent entirely,
lesions which are otherwise inevitable and severe. In
the rabbit, the prophylactic administration of anticoagulants has marked beneficial effects on the development of glomerulopathy. Unfortunately, comparable benefit is not observed when these maneuvers
are performed after glomerular abnormalities are already established.
Most experimentally induced glomerulopathies
are self-limiting and of brief duration. Aside from the
maneuvers mentioned in the previous paragraph,
therapy which would be considered suitable for use in
man appears for the most part to be of little benefit in
the laboratory. In man, the value of currently available treatments intended to halt or reverse the progression of glomerular abnormalities is no more impressive. Corticosteroids, immunosuppressive agents,
and anticoagulants are of proven value in only a
minority of histologically specific lesions (for example, hypersensitivity angiitis, Wegener granulomatosis, minimal lesion nephrotic syndrome), and
their efficacy in other forms of glomerulonephritis is
strongly debated. The very existence of such debate,
over 25 years after the introduction of steroid therapy
and 15 years after azathioprine (Imuran) became
available, should indicate that current treatment
modes are less than optimally effective. New forms of
treatment must be developed.
Working on the assumption that immunologic
mechanisms are the key to the appearance of glomerular injury, one would ideally search for new
MCV QUARTERLY 14(2): 90-91 , 1978
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means of turning off or minimizing the impact of
those mechanisms, an approach which meets with
considerable success in the prevention of renal transplant rejection. Having been largely unsuccessful in
achieving suitable manipulation of immune mechanisms with our present knowledge, we can at least
attempt to minimize the impact of the immune system on the kidney. In that regard, a new approach to
the problem is under study here at the Medical College of Virginia and elsewhere-plasmapheresis. This
technique involves the removal of the patient's
plasma and replacing it with donor's plasma so as to
remove circulating immune complexes and/or preformed antikidney antibodies. Preliminary data indicate that, in selected cases, significant improvement
in renal function may follow such treatment. The
overall value of plasmapheresis is still under review,
however, and will not be known until suitable numbers of patients have received this treatment.
Use of the "Melbourne cocktail"-a combination of dipyridamole, corticosteroid and heparin
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therapy-has been reported to reverse the most fulminating and devastating form of acute glomerular
disease termed "rapidly progressive glomerulonephritis." While the clinical presentation of oligoanuria with virtually complete cessation of glomerular
filtration in children is often completely reversible, it
is rarely so in adults. Fibrin deposition, formation of
luxuriant epithelial crescents, and marked cellular
proliferation of the glomerular tuft typify this subgroup of patients. Employing a treatment which affects platelet aggregation and intracapillary coagulation seems entirely rational but is not without
hazard to the patient. Once this particular form of
fulminating glomerulonephritis is recognized, however, the prognosis for return of renal function is so
poor that the cocktail is being investigated in several
centers. Evaluation of such treatment requires experience, ideal patient management and careful patient
selection, and should be undertaken only under the
most stringent precautions if we a re to establish its
efficacy in a controlled fashion.

The Management of End-Stage Renal Disease
(ESRD)
WILLIAM F. FALLS, JR., M.D.

Medical Service, Veterans Administration Hospital, and Department of Medicine, Medical College of Virginia,
Health Sciences Division of Virginia Commonwealth University, Richmond, Virginia

End-stage renal disease (ESRD) may be defined
as a state of renal insufficiency of such severity that
the affected individual is unable to carry out his usual
activities because of symptoms usually attributed to
the uremic syndrome. This state has been reached, or
is imminent, when the serum creatinine concentration
rises above 10 mg/ 100 ml and/or the creatinine clearance falls below 5 to 10 ml/min and reversible causes
of renal failure such as obstructive uropathy, bilateral
renal vascular disease, severe accelerated hypertension, hypercalcemic nephropathy, uric acid nephropathy, and certain immunologic diseases such as
Wegener granulomatosis have been excluded. Prospective analysis of a population of patients meeting
these biochemical criteria has clearly shown that at
least 80% will require dialysis within 150 days and
40% will require this method of treatment within 60
days to sustain life. 1 Thus, when ESRD is reached,
weighty decisions concerning the patient's care must
be made. It is the purpose of this paper to review the
management of ESRD and to point out some of the
problems which may complicate the several therapeutic modalities.
The alternative methods of management of the
patient with ESRD are dialysis and transplantation.
These two therapeutic modalities are by no means
mutually exclusive and, as we shall see, should be
considered complementary. However, virtually all
patients must undergo a period of dialysis, even those
awaiting transplantation. Therefore, dialysis is the
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first mode of treatment encountered by a patient
entering an ESRD program.
At the present time there are few absolute contraindications to entrance into an ESRD program for
dialysis and transplantation. However, patients with
uncontrolled psychotic behavior, extreme old age,
advanced artherosclerotic vascular disease, or disseminated malignancy are probably not candidates
for therapy.
Principles of good conservative management of
renal failure such as restriction of dietary protein,
careful attention to fluid and electrolyte balance with
tailoring of dietary sodium intake to the obligatory
sodium loss, and the administration of sodium bicarbonate supplements and oral phosphate binders
where appropriate may postpone the absolute need
for dialysis or transpl antation if introduced when the
patient has moderately severe renal insufficiency. Recent studies have demonstrated that the period of
conservative management can be prolonged even further by the administration of a special mixture of the
keto-analogues of the essential a mino acids. 2 This
maneuver allows for the dietary administration of
very limited quantities of nitrogen and is predicated
on the assumption that some of the urea nitrogen will
be recycled into the synthesis of essential as well as
nonessential amino acids. Unfortunately, these ketoacids are not commercially available at present, but
perhaps will be in the future.
Survival rates for patients treated by hemodialysis at home and those who have received a wellmatched transplant from a living related donor are
both greater than 80% at two years.3 It is worth
noting, however, that this represents patient survival
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and not graft survival which is only about 70%, thus
indicating that some 10% to 15% of the transplant
recipients who survive two years have suffered an
undetermined amount of morbidity in association
with rejection of their graft . Survival with in-center
dialysis and cadaver transplantation is less good, with
a two-year survival rate of approximately 70% in each
case. 3 The two-year graft survival in patients with
cadaver transplants is less than 50%. These statistics
suggest the desirability of home dialysis and living
related donor transplantation, but do not demonstrate a clear superiority of in-center dialysis or cadaver transplantation. Thus, factors other than survival
must be considered in selecting a mode of therapy.
Age is a major factor which may influence therapeutic selection. Children and adolescents tend to
have diminished growth and maturation while on
dialysis 4 and they frequently rebel against the rigid
dialysis schedule. Therefore, most authorities favor
transplantation as a mode of therapy in the young. 5
On the other hand, older individuals with a wellestablished, stable lifestyle may prefer not to run the
risk of the lost time from work and the potential
complications of transplantation. The patient's psychological state also may be of importance in selecting a mode of therapy. Some older patients, like the
children, may find the confining life of the dialysis
patient to be more than they can tolerate and be
willing to risk the uncertainties of cadaver transplantation.
The presence of complicating medical disorders
may influence the type of management selected . Diabetics may fare better with transplantation because
progression of atherosclerotic vascular disease and
retinopathy may be less rapid than on dialysis. 5 Patients with certain enzyme defects such as Fabrey
disease may also benefit from transplantation because the transplanted organ may serve as a source of
the defective enzyme. 6 On the other hand, transplantation is contraindicated in patients with antibasement membrane antibody nephritis with circulating antibodies 7 and in patients with large quantities
of circulating cytotoxic antibodies 7 because of the
likelihood of rapid graft destruction after transplantation. Additionally, the immunosuppressive
medication given to patients may allow for enhanced
tumor growth, and most surgeons will not consider
performing transplantation in a patient with a history
of malignancy unless there is clear evidence that the
patient has been tumor-free for at least one year.7 The
presence of lower urinary tract dysfunction and an
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inadequate bladder are still considered relatively
strong contraindications to transplantation.
Having decided that a patient's life will be sustained, a decision must be made about the form of
dialysis to be instituted. Although chronic peritoneal
dialysis has been an effective modality in some
hands, 8 most authorities consider it to be less desirable than chronic hemodialysis, and the remainder of
this discussion will be concerned with hemodialysis.
Two types of vascular access are available for
connecting the patient to a dialysis machine. These
are the silastic, external arteriovenous (AV) shunt 9
which protrudes through the skin and the internal
AV fistula communication, using the patient's own
vessels 10 or a foreign graft material. 11 The latter lies
immediately under the skin and must be punctured
with a needle at each dialysis. The fistula is preferred
by most physicians and patients because of the freedom of movement and the safety which it provides.
Where possible, it is our policy to anticipate the
ultimate need for dialysis and to have the surgeon
electively establish an AV fistula at about the time the
serum creatinine reaches a concentration of8 mg/100
ml. This allows time for maturation of the fistula
prior to its initial use, and obviates the need for
emergency surgery to establish vascular access in an
ill patient.
Hemodialysis is usually initiated in the medical
center, but when the patient has an acceptable helper,
every effort should be made to encourage the couple
to learn home dialysis. The training program can be
mastered by anyone of average intelligence and takes
about two months to complete. As mentioned previously, patients on home dialysis have better survival statistics and are better rehabilitated. 12
Whether dialysis is performed at home or in a
center facility, there are a number of common complications of which the physician should be aware.
Bacterial infection of the shunt or fistula is a frequent
problem that may lead to metastasization and requires aggressive drainage and antibiotic treatment. 13
Hepatitis B infection has been a frequent occurrence
among dialysis patients. 14 It presents a particular
problem in dialysis units because patients may become carriers and transmit the virus to staff and other
patients. Virtually all patients on dialysis have some
degree of anemia .15 In the past, transfusion of potential transplant candidates was kept to a minimum
because of possible sensitization to transplant antigens. However, recent evidence suggests that frequent
transfusions may actually enhance rather than inhibit
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the frequency of organ acceptance. 16 Therefore,
transfusions, particularly of saline-washed red cells,
are now being given with less concern than in the
past. Pericarditis continues to be a frequent and
poorly understood complication in the dialysis patient and it does not always appear to be a manifestation of inadequate dialysis .17 Hypertension is seen
frequently in the dialysis population ahd may be related either to expansion of the extracellular fluid
volume or to the release of pressor substances from
the residual damaged kidneys .18 In the latter circumstance, bilateral nephrectomy may produce a dramatic return of the blood pressure to normal. 19 Neuropathy is frequently noted at the onset of dialysis
but seldom progresses if dialysis is adequate. 20 Impotence is seen more frequently than not in male dialysis
patients, and dialysis against a bath containing a high
concentration of zinc has recently been proposed as
effective therapy .21 As more patients are sustained
alive for prolonged periods of time it is becoming
clear that osteodystrophy22 and accelerated atherosclerosis21 are problems of great magnitude. Therapy
of the former includes the use of oral phosphate
binders to maintain the serum phosphorus concentration levels at normal , and a supplemental vitamin D
preparation to enhance intestinal calcium absorption;
there does not appear to be any effective therapy for
the latter.
Many of the problems mentioned above will be
corrected by a functioning transplant. However,
there are a number of problems which are unique to
the transplant population. Most of the difficulties
associated with early transplant rejection are managed by the transplant team prior to discharge from
the hospital after surgery, and these will not be considered here. Chronic rejection may occur late after
transplantation, is characterized by a slow deterioration in function , and is generally unresponsive to
therapy. Infection remains the major cause of morbidity and mortality among transplant patients. 23 Because of the constant need for immunosuppressive
medication these patients have an increased susceptibility to both common bacterial pathogens and to
opportunistic viruses such as herpes hominis and
cytomegalovirus; fungi such as cryptococcus and aspergillus; and protozoa such as pneumocystis and
toxoplasmosis . Hypertension also is a frequent complication of transplantation and may be difficult to
control. A diabetic diathesis may be brought out by
the administration of steroids as immunosuppressive
agents. 24 Osteoporosis may develop as a complication
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of long-term steroid administration. 24 The constant
immunosuppression may also allow for the development of tumor growth and there is a much higher
incidence of malignancy in transplant patients than in
a comparable, non-immunosuppressed population. 24
Gastrointestinal bleeding is a feared complication of
transplantation that is frequently fatal. 24 Consequently, many transplant surgeons perform prophylactic gastric surgery in any potential candidate
who has the slightest history of ulcer disease.
It is our feeling that selection of a proper therapeutic modality in a patient with ESRD requires
careful consideration of the medical, psychological,
social, and economic aspects of the patieht's illness.
His needs may change through the course of illness
and, as a consequence, the ESRD prescription may
require alteration. Thus, a patient might initially be
managed with home dialysis, receive a living related
donor transplant after a sibling decided to become a
donor, and return to home dialysis after rejection
occurred.
The economic costs of ESRD treatment are staggering. 25 At present there are more than 37,000 individuals receiving some type of ESRD therapy in the
United States at an annual cost of $902 million. By
1982 it is projected that the cost for 55,900 patients
will be 2.3 billion . Most patients are eligible for financial coverage of the major portion of their dialysis or
transplantation cost either via private insurance carrier, Medicare, or the Veterans Administration. At
present the annual cost of in-center dialysis is approximately $23,400 while that of home dialysis is
$12,480. The initial cost of hospitalization for transplant surgery is about $17,000. These estimates do
not include the cost of hospitalization for various
complications of either the dialysis or transplant
state; and, as suggested earlier, these may be formidable.
In the future, dialysis equipment may be made
more compact and a satisfactory portable dialyzer
may Q_e developed. The use of sorbent materials may
allow dialysis with small quantities of fluid, and high
potency antithymocyte globulin may improve the
early survival of cadaver grafts. Techniques also may
be developed for the stimulation of blocking antibodies in the recipient which will allow for improved
graft survival with lower doses of immunosuppressive
drugs. However, none of these innovations seem
likely to dramatically change the management of
ESRD in the near future.
The management of ESRD has been briefly re-
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viewed; both dialysis and transplantation are useful
modalities of therapy and are not mutually exclusive.
Management in a giv'en patient should be designed to
best meet his medical, psychological, social, and economic needs.
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Introduction

At a time when limiting family size has become
of national interest, increasing numbers of married
couples are moving in a different direction-to overcome infertility and conceive children. Reasonably
reliable statistics indicate that approximately 3 .5 million couples, or nearly 15% of those of childrearing
age, are subfertile. If one adds the cases of secondary
infertility, in which a pregnancy or a miscarriage has
already occurred in the marriage but is followed by
years of difficulty conceiving another child, the magnitude of the infertility problem is indeed impressive.
At the personal level, involuntary childless couples
may suffer doubts about their own sexuality and are
often caught in intense emotional, family, and societal pressures emanating from their inability to conceive.
Furthermore, the incidence of infertility seems to
be slowly increasing due to a number of factors including the increased risk of prolonged anovulation
following the use of birth control pills and to adnexal
infections associated with the use of intrauterine devices. Additionally, there is a definite trend by women
to delay having children until later in life and thus to
bypass the time of their optimal fertility potential
between 22 and 26 years of age.
Whether or not the true incidence of infertility is
increasing, there is a definite and substantial increase
in the demand for treatment. This reflects a growing
awareness by childless couples that treatment for infertility in many instances can be effective and that
Correspondence and reprint requests to Dr. 1. William McRoberts, Division of Urology, University of Kentucky School of
Medicine, Lexington , KY 40506
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the number of babies available for adoption have
been sharply reduced by birth control, liberalized
abortion laws, and an increasing tendency of unwed
mothers to keep their babies.
Until recently, most physicians were not particularly enthusiastic about treating patient infertility.
The reasons for this attitude centered around a general pessimism about being able to help the patient,
combined with the fact that the physicians' training
ill-prepared them for evaluating and managing these
patients with the result that male infertility has probably been the most misunderstood item since the IRS
short form. Presently, a more optimistic view is warranted as therapy is now effective in achieving pregnancy for about 45% of these couples.
The objective of this article is to present the most
recent information regarding the clinical aspects of
male infertility and subfertility. The information will
be practical and directed to understanding both the
causes of male infertility and the various methods of
evaluating and managing male patients with this
problem.
Definition of Male Infertility and Subfertility

Based on semen analysis, a precise definition of
male infertility and subfertility is difficult because the
quality of semen that will achieve a pregnancy for one
couple and not another will vary due to the relative
fecundity of the female partner and the variable interaction of infertility co-factors. In other words, data
suggest that there are degrees df fertility for both
sexes, depending on the partner. 1 Nevertheless, given
a female partner who is fertile by most standards,
lower limits for semen quality have been established
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under which a pregnancy is likely to occur. 2 - 4 These
minimal values are as follows:
Total ejaculate volume: 1.5-5.0 ccs
Sperm count: 20 m/ cc
Sperm motility: 60% motile
Sperm speed: 2+ (Scale 1-4)
Sperm morphology: 60% normal forms
These minimal values must be considered as part
of the overall semenogram and may be adjusted if
one index is of particularly high quality, for example,
a patient with a 10 m/ cc sperm density may well be
fertile if his sperm motility is excellent.
History and Physical Examination
Beyond obtaining a basic medical and marital
history, the infertility history should be directed at
uncovering the specific factors that are known to
contribute to subfertility. These factors can be conveniently divided into four groups: childhood illnesses;
adult illnesses; drugs; and environmental-occupational hazards.
Specific childhood illnesses that can adversely
effect fertility include cryptorchidism, mumps, spermatic cord torsion, direct trauma , and the timing of
puberty as well as specific surgical procedures including herniorrhaphy, orchiopexy, hypospadias repair,
urethroplasty, and Y-V plasty of the bladder neck to
relieve "obstruction."
Adult illnesses that are similarly important include tuberculosis of the genital tract, mumps, orchitis, prostatitis, epididymitis, gonorrhea, diabetes,
vaginitis in the female partner, and such surgical
procedures as noted under childhood illnesses plus
retroperitoneal surgery (lymphadenectomy, sympathectomy, and so forth), vasectomy , and prostatic
surgery.
Drugs that are known to interrupt or alter spermatogenesis include the nitrofurantoins, amebicides,
hormones (for example, testosterone, estrogens, corticosteriods ), as well as most of the anti-cancer
chemotherapeutic drugs .
The patient's occupation may have a bearing on
his fertility status if he is under a great deal of stress
or if the testicles are exposed to undue heat or radiation.
The physical examination should include a thorough examination of the external genitalia and prostate. Testicular size and consistency are particularly
important; measurement is facilitated by the use of
calipers. The normal adult testis measures approxi-
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mately 4.6 cm in greatest diameter (range 3.6-5.5 cm)
and 2.6 cm in width (range 2.1-3 .2 cm). Because the
germinal epithelium comprises about 80% of the·normal testicular mass, atrophy of the seminiferous tubules will be reflected in a smaller than normal testicle. On the other hand, normal testicular size does
not assure normal semen quality. If the patient's
body habitus appears abnormal, laboratory investigation should be directed at determining any abnormality of the hypothalmic-pituitary-gonadal axis.
The Semen Analysis
The semen analysis is without doubt the single
most important step in the evaluation of male infertility. It is to male infertility what cystoscopy is to
bladder tumors, that is, it is the most critical item in
the initial eva luation process and is important in
therapy foll ow-up .
The semen analysis, or semenogram, is a study
of the ch aracteristics of the sperm atozoa that are
clinically important in assessing fertility. While noncellular components of the semen also contribute to
fecundity, for clinical purposes the semenogram will
reflect their influence on the spermatozoa! characteristics that are decisive in determining fertility potential, and a separate biochemical analysis of these
components is neither necessary nor practical.
Because of its importance, a minimum of two
and preferably three semen analyses should be obtained. Additionally , multiple collections are necessary because of physiological variations in the same
patient and because of technical variations in analyzing the specimen, for example, acceptable counting
errors vary from 10% to 20% with the same specimen.
Preferably, the semen specimen should be collected by masturbation into a clean, wide-mouthed
glass or pl astic container. The container, such as a
standard urine specimen bottle or ointment jar,
should be supplied by the physician to avoid factitious results secondary to the container's previous
contents or cleaning agents. The specimen should be
kept warm and delivered to the laboratory for analysis within 60-90 minutes. The timing of specimen
collection should reflect the couple's usual coital frequency pattern, or if that is vari able, an abstinence
period of 2-4 days is recommended . Personal or religious beliefs may require the use of a silastic seminal
fluid collecting device. It is critical that the specimen
represents the entire ejaculate since there are significant variations in the seminal values from one portion to the other with regard to motility, sperm den-
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sity, and viscosity as compared with the total
ejaculate.
The specific techniques of analyzing the semen
will not be discussed because they are beyond the
space limitations of this presentation and, additionally, are available in recent texts. 5 Five principal indices should be reported on the semen analysis. Representative values for fertile men are as follows:
1. Total ejaculate volume: 2-5 ccs
2 . Sperm count (density in millions/ cc): greater
than 50 m / cc
3. Sperm motility(% motile cells): 65% to 85%
4 . Sperm speed (forward progression speed): 3-4
(scale 0-4)
5. Sperm morphology: 60% to 85% normal oval
forms
Additionally: The specimen is normally viscous
a nd opalescent with a grayish-white color. There
should be no hyperviscosity, pyospermia, or significant sperm agglutination.
Systematic Approach to Male Infertility
A systematic approach to male infertility can be
facilitated with the use of the following diagnostic
flow sheet (modified after Lipshult z6 ):

HISTORY

1-----1

PHYSICAL
EXAMINATION

SEMEN ANALYSIS

X3

SEM EN
ANALYSIS

NORMAL

I

Evaluate couple
ABNORMAL

ASPERMIA AND
AZOOSPERMIA

ALL
PARAM ETE RS ABNORMAL

PREDOMINANCE OF SINGLE ABNORMAL PARAMETER

The flow sheet is based on the semen analysis
and the identification of the three broad seminal categories of: 1) aspermia and azoospermia, 2) predominance of a single abnormal parameter, a nd 3)
all parameters abnormal.

Aspermia and Azoospermia
Somewhat less than 5% of male infertility patients will present with either aspe rmia or azoospermia. In the aspermic patient there is failure of
any ejaculate to appear at the time of orgasm. On the
other hand , the azoosperm ic patient experiences both
ejaculation and orgasm, but the ejaculate contains no
spermatogenic elements .
The absence of ejaculatio n in aspermic patients
is generally due to neurogenic causes 7 and, less commonly, to retrograde ejaculation. The neurogenic
causes includ e pituitary tumors, olfactogenital dysplasia (Kallman syndrome), and absent contraction
of the seminal vesicles and vasa differentia following
retroperitoneal lymph node dissection for the treatment of testi cu lar tumors (and not due to retrograde
ejaculations as previously thought) .
The neurogenic causes can be successfully
treated in most cases by specific replacement therapy.
The common causes of retrograde ejaculation
include those in which the anatomy of the internal
sphincter is disrupted as in transuretheral resection (TUR) of the prostate or vesicle neck surgery,
or where the nerve supply of the internal sphincter
is distrupted as in spinal cord injury , surgical sympathectomy, chemical sympathectomy [guan ethidine
(sulfate) (Jsmelin)), and diabetes visceral neuropathy.
Apart from a history of a previous elective vasectomy, the azoospermic patient's differential diagnosis
rests bet ween obstruction or atresia of the epididymal
or vasal ducts and testicular failure as seen in germinal cell aplasia, marked spermatogenic arrest,
chromosomal defects, severe peritubular fibrosis, a nd
Klinefelter syndrome .
The seminal specimens of all azoospermic pati ents should be tested for the presence or absence of
fructose: this is quantitatively determined by adding
the reducing reagent resorcinol to a small portion of
the seminal specimen and bringing it to a boil. 5 If
fructose is present, an orange color will appear within
half a minute of boiling. The presence of fructose, a
product of the seminal vesicles, effectively rules out
congenital bilateral absence of the vasa as the presence of the seminal vesicles depends on the existence
of the vasa which embryologically give rise to the
former. On the other hand, the presence of fructo se
only rules out bilateral obstruction of the ejaculatory
ducts but does not assure ductal patency throughout
the vasa and epididymi . Therefore, in a setting of
azoospermia and a normal testicular biopsy, vasograms should be obtained to identify the site of ob-
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struction which can be corrected surgically by microsurgical techniques, depending on its location.
Predominence of a Single Abnormal Parameter
Approximately a third of subfertile male patients
will have a semen analysis characterized by the predominence of a single abnormal parameter, most
commonly sperm viability/motility. Asthenospermia,
a decrease in sperm motility below 60%, can be
caused by a number of factors including sperm immobilizing antibodies, infection, endocrinopathy,
varicocele, and epididymal dysfunction.
It is now widely appreciated that testicular
spermatozoa acquire their fertilizing capacity and
motility as they pass through the epididymis. Important for these considerations is the fact that testosterone is transported, bound to androgen-binding-protein, from the seminiferous tubular fluid to the
epididymis in concentrations about 20 times that of
serum. In the epididymis, the antigen-binding-protein
disappears and the free testosterone diffuses into the
epididymal cell. Therefore, the functional integrity of
the epididymis may be compromised either by failure
of the Leydig cells to produce high enough local
concentrations of testosterone, by failure of the Sertoli cells to produce adequate amounts of androgenbinding-protein, or by failure of the epididymal epithelium to utilize effectively the free testosterone. In
any event, the end result is a local epididymal environment not optimal for the normal development of
sperm motility. Therapy is directed at improving the
local epididymal environment by the administration
of gonadotropins which stimulate Leydig cell production of testosterone and androgen-binding-protein by
the Sertoli cells. Therapy has been effective in somewhat less than half the patients so treated. Low-dose
androgen therapy in the form of fluoxymesterone
(Halotestin) 2-5 mg, b.i.d., has not been effective.
Additionally, epididymal dysfunction may be
secondary to complete or partial obstruction, or to
changes in the functional integrity of the epididymis
itself due to such conditions as epididymitis. Treatment is directed at the specific disorder and involves
short-circuiting the obstruction by microsurgical
techniques and by appropriate antibiotic treatment of
the epididymitis.
The most profound manifestation of a viabilitymotility / disorder is necrospermia which fortunately
is rare as there is no successful treatment.
In patients with high ejaculate volumes (>3.5
ml) and a secondary decrease in sperm count ( oli-
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gospermia of less than 20 million/ ml), sperm density
may be improved in about 80% of patients by use of
the split-ejaculate technique. To collect a split or
fractionated ejaculatory specimen, the patient is
given two collection jars which are numbered #1 and
#2 and s.ecured together with adhesive tape. The first
one third of the ejaculate is collected in jar #1 and the
remainder in jar #2. In 80% of patients, the sperm
density will be significantly higher in the first portion
of the ejaculate. The more favorable first portion may
be delivered to the cervical os by a withdrawal coital
technique (penis withdrawn from the vagina after the
first spurt of ejaculate) or by insemination. In properly selected cases, pregnancy results are about 60%.
Diffuse Abnormality of All Seminal Parameters
The most common (60%) abnormal presentation
of the semen analysis is a diffuse abnormality of all
seminal parameters, that is, low sperm density, poor
sperm viability, and more than 40% abnormal sperm
forms. While nonspecific stress, subclinical endocrinopathy, and epididymal dysfunction or block are
rare causes of diffuse seminal abnormality, they must
nevertheless be considered and treated.
However, the most common cause of diffuse
seminal abnormality is a varicocele which accounts
for one third of all cases of male infertility. The
varicose enlargement of the veins of the spermatic
cord (pampiniform plexus) is caused by valvular incompetence of the internal spermatic vein with secondary retrograde flow of venous blood from the left
renal vein into the internal spermatic vein. Because of
the characteristic anatomy of the internal spermatic
vein on the left side, varicoceles clinically occur more
commonly on that side, that is, 80% left, 19% bilateral, and I% right. Even if a varicocele is clinically
limited to one side, venous dilatation occurs bilaterally due to the liberal cross-venous circulation of
the pampiniform plexus, and the germinal epithelium of both testes is pathologically affected.
Varicoceles are best diagnosed with the patient
standing erect as recumbency will decompress the
varices. Small varicoceles can be more readily appreciated by having the patient perform a Valsalva maneuver. The diagnosis of small, subtle, and even subclinical varicoceles can be facilitated by use of the
Doppler stethoscope8 ; their diagnosis is equally important as there is no correlation between the size of
the varicocele and the reduction in spermatogenesis
based on testicular biopsies and semen analyses. 9
The mechanism whereby the varicocele causes
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the deleterious effect on the germinal epithelium remains unresolved. But of the two principal postulated
causes (venous reflux of adrenal "toxins" vs increased
intrascrotal temperatures secondary to venous
stasis), the weight of recent.evidence favors elevated
iritrascrotal temperatures as the probable cause of
depressed spermatogenesis.
The treatment of varicoceles is surgical and is
directed at preventing retrograde venous flow by interrupting the course of the internal spermatic vein at
the level of the inguinal canal (I vanissevich method ) 10
or the retroperitoneum (Palomo procedure ). 11 Attempts to directly remove the dilated scrotal veins
through a transscrotal incision are to be avoided as
they are not effective.
The overall results of surgery are excellent with
an improvement in semen quality of 70% and a pregnancy rate of 45%.

Conclusion
The prognosis for a previously infertile couple of
achieving a pregnancy has improved substantially
over the past 5-8 years. This has been made possible
by a variety of diagnostic and therapeutic advances
based on a greater understanding of t~sticular and
epididymal function and disorder, hypothalamic-pituitary-gonadal interrelationships, and reproductive
immunological and physiological factors. This
knowledge, combined with a more comprehensive
and systematic approach to the evaluation and management of the infertile male patient, has made possible the identification of the cause in 80% of patients
as well as effective therapy in approximately 50% of
coupfes under the age of 30 and approximately one
third of those who are older.
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Introduction
Varying techniques of measurement coupled
with lack of sufficient data have presented great difficulties in the comparison of dental a rch dimensions
obtained by different workers . Several a uthors 1 - 7
have attempted to delineate th e arches. Lavelle et
al7 measured the denta l arches of adults from several
different ethnic groups and found little difference between the modern British Caucasian, Australian aborigines, and North American Indians. They did, how-
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ever, see considerable differences between these
modern population s a nd a group of Anglo-Saxons
and a group of West Africans.
Severa l studies8 - 10 have sh own that there has
been a reduction in the dimensions of the maxilla and
mandible in modern times, a lth o ug h no reduction in
tooth size was reported. A va riety of explanations
have been put forth to explain this reduction in jaw
size, among them evolutionary change" and consistency of diet. 12 Others 13 - 16 have shown that bone
size is a ffected by mechanical stress or the lack of it.
Since the modern di et is softer than that of past
peri ods, it is reasoned th a t the soft diet requires less
mech an ica l force to m asticate a nd thu s less mecha nical stress on the bone. This reduction in mechanical
stress is assumed then to lead to reduction of jaw size.

IOI
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The present study was undertaken to investigate
any changes in jaw size that occurred within the time
period (2300 years) encompassed by the six pre-Columbian Peruvian cultures studied, and from that
period to modern times.
Materials and Methods
Measurements were made on 84 adult maxillae
and 114 adult mandibles from the pre-Columbian
Peruvian material housed in the Museo Regional de
lea, lea, Peru; these were made up of the following
number of specimens from each of the six cultures:
Paracas, 33 maxillae and 33 mandibles; Nazca, 6
maxillae and 20 mandibles; Huari, 10 maxillae and 14
mandibles; lea, 19 maxillae and 24 mandibles; Inca, 1
maxilla and 2 mandibles; and Colonial, 15 maxillae
and 21 mandibles. These six cultures flourished during the following periods: Paracas, 600 BC-AD 100;
Nazca, 100 BC-AD 800; Huari, AD 800.:_AD 1200; lea,
AD 1200-AD 1450; Inca, AD 1450-AD 1532; and Colonial, AD 1534-AD 1700. The dating of this material
was carried out by both archaeological and C-14
dating. Sex determinations were carried out as outlined by Allison and Gerszten, 17 although these could
not be made accurately on some of the material; the
values for this unsexed material appear in the tables
under the heading "unknown."
A total of 12jaw dimensions were measured; 4 of
the maxilla and 8 of the mandible. The dimensions of
arch width were measured between the centers of the
corresponding teeth ori each side of the dental arch at
the first premolars, first molars and second molars in
both the maxillae and mandibles. Maxillary arch
length was measured as outlined by Moyers. 18 All
measurements of the maxilla were made using dial
calipers with an accuracy of 0.1 mm. Measurements
of the mandible were taken 19 using dial calipers with
an accuracy of 0.1 mm and a mandibular board.
While the measurements of the maxillary and mandibular arch widths at the first premolar and the first
and second molars have been explained, the maxillary arch length and the other mandibular measurements must be defined. Maxillary arch length was
measured by laying a bar across the central fossae of
the first molars and measuring from the midline point
along this bar to the incisal edge of the central incisors. The mandibular angle is the angle between the
standard horizontal plane and the ramal planes. The
height of the ramus is from the most superior point
on the left condyle to the standard horizontal plane
(base of mandibular board) measured in the vertical

plane. The body length is from the most anterior
point in the symphysis area to the intersection of the
standard horizontal and ramal planes. Bigonial width
is the maximum width between the right and left
gonion of the mandible. Bicondylar width is the maximum width between the lateral points of the right
and left condyles. Although Hrdlicka4 states that bicondylar measurement is completely useless as the
width is affected by the width of the skull at its base,
many other authors have used bicondylar measurement to define the mandibular arch and it is, therefore, included in this study.
While 84 adult maxillae and 114 adult mandibles
were measured, all totals for each of these measurements will not come to these numbers because of
missing teeth, fractured condyles, and other factors.
Results
Females in all cultures shown in Table I have the
larger maxillary arch size in three of the four measurements made. Maxillary arch width at the first
premolar is larger in males in all cultures except the
lea. No reduction of maxillary arch size is seen during the approximately 2300-year period studied in
this pre-Columbian Peruvian culture except in the
width of the arch at the first molar; a reduction is seen
here from the most ancient cultures studied to the
most modern. The Inca culture exhibited the smallest
maxillary arch length while the Huari culture, followed closely by the N azca, sho.wed the greatest. The
smallest arch width at the maxillary first premolar
was seen in the Inca culture and the Colonial exhibited the largest width. The largest arch width at the
maxillary first molar was seen in the Nazca culture;
the Colonial had the most narrow arch at the first
molars. The H uari displayed the smallest and the lea
the largest arch widths at the maxillary second molars.
Table 2 gives five mandibular jaw measurements.
The males of this pre-Columbian Peruvian population exhibited the larger arch width at the first
mandibular molar, the larger bigonial width, and the
larger bicondylar width; other measurements presented (mandibular arch width at the first premolar
and second molar) were similar in both sexes. A trend
toward smaller mandibular jaw size was evident by a
reduction in jaw size at the first molar, second molar,
and bigonial widths . The N azca culture and the Paracas culture had the largest mandibular arch widths at
the first premolars. The arch width at the first and
second mandibular molars and the bigonial width
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TABLE 1
Maxillary Arch Measurements
MAXILLARY
ARCH
LENGTH

MAXILLARY ARCH
WIDTH AT
FIRST PREMOLAR
M

F

u

T

M

F

u

T

22
39.6
0.6

0

0

33
48.8
0.6

33
48.8
0.6

0

0

28
53.6
2.8

28
53.6
2.8

4
39.9
0.7

6
39.8
1.0

1
53.4
0.0

0

5
49.6
0.3

6
50.3
0.7

1
57.0
0.0

1
51.4
0.0

3
54.3
1.8

5
54.3
1.3

36.3
0.0

4
39.9
0.8

6
39.4
0.8

1
47.2
0.0

2
48.0
2.5

7
47.8
1.1

10
47.8
0.8

1
52.3
0.0

2
52.8
2.9

6
53.1
1.0

9
52.9
0.8

1
39.4
0.0

13
39.7
0.5

1
39 .0
0.0

15
39.6
0.4

I
50.7
0.0

11
48.7
0.8

7
45. 8
1.9

19
47.8
0.9

1
52.7
0.0

7
54.6
0.7

2
56.7
0.7

10
54.8
0.6

1
24.8
0.0

0

0

1
36.9
0.0

1
36.9
0.0

0

0

1
47.9
0.0

1
47.9
0.0

0

0

1
54.2
0.0

1
54.2
0.0

15
25.l
0.4

2
42.4
0.3

12
40.0
0.6

0

14
40.3
0.5

1
45.6
0.0

10

2
46.4
1.0

13
47 .8
0.5

1
52.3
0.0

11
53.6
0.7

0

48.3
0.6

12
53.5
0.7

M

F

u

T

M

F

u

T

0

0

6
25.4
0.9

6
25.4
0.9

0

0

22
39.6
0.6

Nazca
N
Mean
S.E.

1
22.7
0.0

0

3
27.2
1.1

4
26.1
1.4

1
36.1
0.0

1
36.1
0.0

Huari
N
Mean
S.E.

1
27.0
0.0

0

4
26.8
1.0

5
26.8
1.0

40.3
0.0

lea
N
Mean
S.E.

1
25.3
0.0

9
27.0
0.7

4
26.2
0.9

14
26.7
0.5

0

0

1
24.8
0.0

0

12
24.9
0.4

3
25.9
1.2

CULTURE
Paracas
N
Mean
S.E.

Inca
N
Mean
S.E.
Colonial
N
Mean
S.E.

MAXILLARY ARCH
WIDTH AT
SECOND MOLAR

MAXILLARY ARCH
WIDTH AT
FIRST MOLAR

M =male
F = female
U = sex unknown
T =total
N = number
S.E. = standard error

were larger in the Nazca culture. The Huari, followed
closely by the N azca culture, had the greatest bicondylar width. The mandibular jaw size measurements presented in Table 2 were consistently smaller
in the Inca culture, although this figure can be misleading due to the small sample size.
For three other mandibular jaw measurements
(mandibular angle, ramus height, and body length)
presented in Table 3, the male specimens in this study
have the larger measurements, although no reduction
in jaw size is seen from the most ancient to the most
modern cultures. The Paracas culture exhibits the

largest mandibular angle and the N azca the smallest
m this pre-Columbian Peruvian population. The
Paracas culture shows the smallest ramus height and
the Colonial has the greatest. In examining the body
length measurements, the Nazca culture specimens
have the longest mandibular body and the Inca have
the shortest.
Discussion
The size and shape of the dental arches are subject to considerable variation. 3 Factors such as
growth 20 and the location of the teeth in relation to

0

~

TABLE 2
Mandibular Jaw Width

MANDIBULAR ARCH
WIDTH AT
FIRST PREMOLAR

MANDIBULAR ARCH
WIDTH AT
SECOND MOLAR

BICONDYLAR WIDTH

BIGONIAL WIDTH

u

T

M

F

u

T

M

F

u

T

M

F

u

T

19
34.9
0.5

19
34.9
0.5

0

0

18
44.8
0.6

18
44.8
0.6

0

0

14
49.8
0.7

14
49.8
0.7

I
96.0
0.0

I
96.0
0.0

28
93.3
1.4

30
93 .5
1.3

32
30
121.5 112.0 116.9 116.9
0.0
0.0
1.7
1.6

JO
34.8
0.5

12
34.9
0.4

I
48.2
0.0

I
43.7
0.0

14
46.5
0.4

16
46.4
0.4

0

13
51.4
0.4

14
51.7
0.6

I
90.0
0.0

I

35.4
0.0

s1.5
0.0

18
95.0
2.1

20
95.8
2.4

I
I
18
20
111.0 118 .0 118.5 118.J
0.0
0.0
1.3
1.3

I
32.5
0.0

2
33.8
0.4

8
34.1
0.6

II
33.9
0.5

42.6
0.0

42.3
0.0

7
45 .9
0.4

9
45.2
0.6

47.0
0.0

6
51.6

1.2

7
50.9
1.2

2
101.5
0.0

2
85.8
0.2

9
93.4
1.7

13
93.5
1.7

2
2
13
9
124.0 120.5 118.1 118.6
2.5
1.0
1.8
2.3

2
37.2
2.5

14
35.0
0.5

4
33.3
1.2

20
34.9
0.5

I
49.2
0.0

II
45.5
0.8

8
44.4
I. I

20
44.9
0.7

I
52.4
0.0

JO
49.8
0 .6

56.3
0.0

12
50.4
0.8

4
94.1
3.0

16
93 .6
1.3

7
90.4
2.2

27
92 .8
1.4

4
17
7
28
119.3 118.9 117.2 118.5
1.8
1.2
3.0
I. I

0

0

I
31.3
0.0

0

0

0

0

I
48.1
0.0

0

31.3
0.0

I
48.J
0.0

94.0
0.0

I
88.0
0.0

2
91.0
3.0

I
32.8
0.0

20
34.7
0.4

0

10
48 .6
0.6

3
95.2
2.6

18
90.0
1.7

2
80.8
1.8

23
88.0
1.6

M

F

0

0

Nazca
N
Mean
S.E.

35.5
0.0

Huari
N
Mea n
S.E.
lea
N
Mean
S.E.

CULTURE
Paracas
N
Mea n
S.E.

55.7
0.0

M

F

u

T

C/J

0

>
~
....:

tT'l
;.:I
tT'l

Inca
N
Mean
S.E.
Colonial
N
Mean
S.E.

MANDIBULAR ARCH
WIDTH AT
FIRST MOLAR

-l

>
r:'
'1'
;.:I
tT'l
I

3
34.3
0.8

M =male
F = fema le
U = sex unk nown
T = total
N = n umber
S.E. = standard error

16
35.0
0.4

43.8
0.0

9
43 .3
0.2

42 .6
0.0

42.6
0.0

0

10
43.3
0.2

0

10
48.6
0.6

0

2
118.5 111.0 114.8
3.8
0.0
0.0

3
17
21
121.7 116.7 115.0 117.3
3.4
1.0
0 .0
1.0

("')

0
r

c

s:l:C
;;:
z

'1'

tT'l
;.:I

c

<

;;:
z

._

>
~

C/J

N
tT'l
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TABLE 3
Other Mandibular Measurements
MANDIBULAR ANGLE
M

F

u

T

M

Paracas
N
Mean
S.E.

I
115.0
0.0

I
121.5
0.0

31
121.3
1.0

33
121.l
1.0

Nazca
N
Mean
S.E.

118.0
0.0

114.5
0.0

18
118 .0
1.7

Huari
N
Mean
S.E.

2
123.5
3.0

2
116.5
5.0

lea
N
Mea n
S.E.

4
119.5
3.8

16
116.9
1.3

CULTURE

Inca
N
Mean
S.E.
Colonial
N
Mean
S.E.

0

3
117.0
5.6

BODY LENGTH

RAM US HEIGHTH

F

u

T

M

F

u

T

63.0
0 .0

53.5
0.0

30
56.8
1.2

32
56.9

l.l

I
82.0
0.0

71.5
0.0

29
74.1
1.0

31
74.3
1.0

20
117 .9
1.5

I
60.0
0.0

55.0
0.0

18
60.1
1.0

20
59.8
1.0

68.5
0.0

I
68.0
0.0

18
78.3
1.3

20
77.3
1.3

IO
119.8
1.7

14
119.8
1.4

2
60.8
2.3

2
55.8
1.8

JO
59.6
2.3

14
59.2
1.7

2
76.2
1.2

2
76.3
2.8

JO
73. l
2.5

14
74.7
2.1

5
122.0
3.5

25
118.3
2.4

4
59.0
I. 7

17
60.2
0.8

6
59.4
1.8

27
60.6
0.6

4
78.9
2.1

16
75.3
1.0

8
73.3
2.4

28
74.J
1.2

I
59.5
0.0

2
57.0
2.5

0

54.5
0 .0

71.0
0.0

I
74.0
0.0

2
72.5
1.5

16
60.0
I. I

2
56.3
1.3

21
60.0
1.0

3
74.8
1.4

16
75.6
1.0

2
76.0
0.0

19
75.0
0.0

I

I

I
116.0
0.0

2
118.8
2.8

0

121.5
0.0

17
117.5
1.6

2
124.5
0.0

22
118.5
1.5

3
62.3
2.0

M = male
f" = female

U = sex unknown
T = total
N = number
S.E. = standard error

the basal bone21 have been shown to influence arch
size and shape. Gould and Picton 22 pointed out that
the equilibrium between the adjacent orofacial musculature and the arch affects its size and shape. The
degree of tooth attrition or abrasion has also been
noted to affect arch size and shape. Several of these
factors, particularly attrition and growth, could have
influenced jaw size and shape in this study, giving the
wide degree of variation seen between and within the
cultural groups .
Studies of Swedish maxillae and mandibles, 8
British palates 10 and dental arches, 23 and European
mandibles, 24 have all shown a reduction in jaw di-

mensions in recent times in Europe. Several of these
studies have also shown that this reduction was not
accumpanied by a corresponding diminution in tooth
size. The present study shows a reduction in the width
of the maxillary arch at the first molar during the
time period studied. The most recent pre-Columbian
Peruvian cultures also showed a reduction in jaw size
in the mandible as noted in the diminution of arch
width at the first and second molars and in the bigonial width. This reduction in jaw dimensions in more
recent times was, however, accompanied by a corresponding reduction in tooth size. 25
Many authors 26 •27 •12 have blamed this reduction
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of jaw size on soft diet. The soft diet requires little
mechanical force to masticate and thus less stimulation of the bone. If changes in the consistency of the
diet were the principal factor responsible for this
reduction , then the mandibular ramus would be reduced in size. 28 One should bear in mind that the
mandibular ramus is the point of insertion of the
muscles of mastication. In the present study, while a
reduction in jaw size was exhibited by the more modern cultures as compared to the earlier ones, a reduction in the mandibular ramus was not seen. Although
the presumptive evidence is strong that the reduction
of the jaws is the direct result of less mecha nical stress
produced by the mastication of a soft diet in some
studies, the possi bility that genetic change may also
be involved cannot be completely ruled out. Archaeological study of these cultures has shown that while
differences in diet were seen between " inland" and
"coastal" cultures, little change occurred in the diet
within these groups over the period studied. The influx of outside groups of individuals into the cultures
studied, either by conquest or peaceful assimilation,
could have resulted in the acquisition of new genetic
traits, which leaves open the possibility that genetic
change has influenced the reduction in jaw size.
Conclusion
In this study of 84 adult maxillae and 114 adult
mandibles a reduction in jaw dimensions was seen in
the more modern cultures. This reduction could not
be explained by diet alone and the possibility that
genetic change from gene mutation or population
migration is s uggested . Due to the small number of
male specimens identified in this population, few, if
a ny, valid compa risons can be made between the
sexes concerning jaw dimensions. Future studies
should be conducted to remedy this discrepancy.
REFEREN CES

5. HRDLICKA A: Lower jaw. l. The gonial angle. II. The bigonial
breadth. Am J Phys Anthropol 27:281-308, 1940.
6. LAVELLE CLB, FLINN RM, FOSTER TD, ET AL: An analysis
into age changes of the hum a n dental a rch by a multivariate
technique . Am J Phys Anthropo/ 33:403-411, 1970.
7. LAVELLE CLB, FLINN RM, FOSTER TD, ET AL: Differences in
growth of the dental arch in some "races" of man . J Anat
I 07: 182-1 83, 1970.
8. LYSELL L: A bometrical study of occlusion and dental a rches
in a series of mediaeval sku ll s from northern Sweden. A eta
Odon/ S cand 16:177-203, 1958.
9. BRASH JC: The aetio logy of irregula rity and maloccl usion of
the teeth. Dental Board of the United Kingdom, Lo ndon,
1929.
10. GoosE DH : Red uction of palate size in modern populations.
Arch Oral Biol 7:343-350, 1962.
11. KEITH A: Concerning certain structural changes which a re
taking place in our jaws and teeth. Dental Board of the United
Kingdom, London, 1924.
12 . WALLACE JS: Variation in the Form of 1he Ja ws. London ,
Bai lliere, Tindall , a nd Cox, 1927.
13. WATT DG , WILLIAMS CHM: The effects of the physical consistency of the food on the growth and development of the
mandible a nd maxilla of the rat. Am J Onhodont 37:895-928,
195 1.
14. GILLESPIE JA: The nature of the bone changes associated with
nerve injuries and disuse. J Bone Join! Surg 36B:464-473,
1954.
15. MOORE WJ: Masticatory function a nd skull growth. J Zoo!
Proc Zoo! Soc L ondon 146: 123-13 1, 1965.
16. MOORE W J: Muscular function and skull growth in the laboratory rat (Rattus norvegicus). J Zoo/ Proc Zoo/ Soc L ondon
152: 287-296, 1967.
17. ALLISON MJ, GERSZTEN E: Paleopathology in Peruvian mummies. Application of modern techniques. Richmond, Virginia
Commonwealth University, 1975.

I. THOMS EN S: Dental morphology and occlusion in the people of
Tristan da Cun ha. Results of the Norwegian Scientific Expedition to Tristan da C unha, 1937-38. No . 25, Oslo, 1955.

18 . MOYERS RE: Handbook ofOnhodontics, 3 ed. Ch icago, Yea rbook Medical Publishers, In c, 1973, p 198.

2. AITCH ISON J: Some racial contrasts in the teeth and dental
arches. Dental Magazine and Oral Topics 82:20 1-205, 1965.

19. MORANT GM: A biometric study of the h uman mandible.
Biometrika 28:84-122, 1936.

3. MOORE ES CFA: The Aleut Dentition. A Correlative Study of
Dental Cha racteristics in an Eskimoid People. Cambridge,
Ha rva rd University Press, 1957.

20. SILLMAN JH: Some aspects of indi vidual dental development:
Longitudin al study from birth to 25 years. Am J Orthodont
51: 1-25, 1965.

4. HRDLICKA A: Lower jaw. Further st udies. Am J Phys Anthropol 27: 383-4 76, 1940.

21. MARTINEK CE: A comparison of va rious surveys o n the adequacy of basal bone. Am J Onhodont 42:244-254, 1956.

SA WYER ET AL: PRE-COLUMBIAN PERUVIAN JAW SIZE

107

22. Gouw MSE, PICTON DCA: A study of pressures exerted by

25. SAWYER DR: The Oral Paleopathology and Odontology of Pre-

the lips and cheeks on the teeth of subjects with Angle's class
II division l, class II division 2 and class III malocclusions
compared with those of subjects with normal occlusions. Arch
Oral Biol 13:527-541 , 1968.

Columbian Peruvians, thesis. Medical College of Virginia,
Richmond, 1977.

23. LAVELLE CLB: The. British dental arch . Am J Phys Anthropol
41:63-69, 1974.

24. MOORE WJ, LAVELLE CLB, SPENCE TF: Changes in the size
and shape of the human mandible in Britain. Br Dent J
125: 163-169, 1968.

26. KLATSKY M: Etiological factors in dental degeneration. A
study in physical anthropology, abstract. J Dent Res 24: 117,
1945.
27. PICKERILL HP: The Prevention of Dental Caries and Oral Sepsis, 3 ed. London, Bailliere, Tindall and Cox, 1923.
28. LAVELLE CLB: A comparison between the mandibles of Romano-British and nineteenth century periods. Am J Phys Anthropol 36:213-219, 1972.

A normal reaction to emotional stress is a marked
increase in both the strength and frequency of wave-like
contractions of colonic motility. 1 However, in the patient
with irritable bowel syndrome, this psychovisceral
reacti on is of greater intensity and duration than normal. 2
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When spasm and pain associated with irritable bowel
syndrome call for treatment beyond your counseling and
reassurance, Donnatal may prove to be a helpful adjunct.
The smooth central sedation and prompt peripheral
antispasmodic/anticholinergic action of Donnatal may
provide this symptomatic relief necessary to help calm
the waves ... and quell the spasm.
References: 1. Almy, TP, Kern, F, and Tulin, M.: Alterations in colonic function in
man under stress. II: Experimental production of sigmoid spasm in healthy persons.
Gastroenterology 12(3):425-436, 1949. 2. Almy, TP, Hinkle, L.E., Berle, B., et al.:
Alterations in colonic function in man under stress. Ill: Experimental production of
sigmoid spasm in patients with spastic constipation. Gastroenterology
12(3):437-449, 1949.
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